Denovo Structural Modeling and B cell and T cell Epitope Prediction against SARS-COV-2 PLpro to Cure COVID-19: Vaccinomics Based Approach

Article Information

Fabian JS van der Velden1,2, Priyen Shah3, Marie Voice4, Emma Lim1, Jethro Herberg3, Victoria Wright3, Tisham De3, Enitan D. Carrol5,6, Aakash Khanijau5, Andrew J Pollard7, Stéphane Paulus7, Ulrich von Both8, Laura Kolberg8, Clementien L Vermont9, Nienke N Hagedoorn9, Federico Martinón-Torres10,11,12, Irene Rivero Calle10, Philipp KA Agyeman13, Luregn J Schlapbach14, Maria Tsolia15, Irini Eleftheriou15, Marko Pokorn16, Mojca Kolnik16, Taco W Kuijpers17, Dace Zavadska18, Aleksandra Rudzate18, Nina A Schweintzger19, Werner Zenz19, Shunmay Yeung20, Michiel van der Flier21,22, Ronald de Groot21, Michael Levin3, Colin Fink4, Marieke Emonts1,2,23,*, on behalf of the PERFORM consortium**

1Great North Children’s Hospital, Paediatric Immunology, Infectious Diseases & Allergy, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

3Wright-Fleming Institute, Section of Paediatric Infectious Disease, Imperial College London, London, United Kingdom

4Micropathology Ltd, University of Warwick, Warwick, United Kingdom

5Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom

6Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom

7Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom

8Division Paediatric Infectious Diseases, Dr. Von Hauner Children’s Hospital, University Hospital, LMU, Munich, Germany

9Department of Pediatrics, Division of Pediatric Infectious Diseases & Immunology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands

10Pediatrics Department, Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

11GENVIP Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain

12Consorcio Centro de Investigacion Biomedicaen Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

13Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

14 Department of Intensive Care and Neonatology, and Children’s Research Center, University Children’s Hospital Zürich, Zürich, Switzerland

152nd Department of Pediatrics, National and Kapodistrian University of Athens, Children’s Hospital ‘P, and A. Kyriakou’, Athens, Greece

16University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

17Amsterdam University Medical Center, location Academic medical Center, Department of Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands

18Department of Pediatrics, Rigas Stradina Universitate, Children’s Clinical University Hospital, Riga, Latvia

19Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical University of Graz, Graz, Austria

20Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom

21Pediatric Infectious Diseases and Immunology, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, The Netherlands

22Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

23NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom

*Corresponding author: Marieke Emonts, Great North Children’s Hospital, Paediatric Immunology, Infectious Diseases and Allergy, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

**Members of the PERFORM Consortium are listed in the supplementary files

Received: 01 August 2023; Accepted: 09 August 2023; Published: 14 September 2023

Citation: Carlos Eliel Maya Ramirez, Sajida Ashraf, Faiza Irshad, Tabish Rehman, Moayad Shahwan, Muhammad Sufyan. Denovo Structural Modeling and B cell and T cell Epitope Prediction against SARS-COV-2 PLpro to Cure COVID-19: Vaccinomics Based Approach. Journal of Bioinformatics and Systems Biology. 6 (2023): 209-262.

Share at Facebook

Abstract

Background: In December 2019, SARS COV-2 spread very rapidly and its outbreaks led to cause pneumonia and severe illness. For the first time, the virus was spotted in the city of China (Wuhan). Little is known about this virus, so the vaccine is needed to prevent COVID-19. Papain like protease (PLpro) is conserved among coronaviruses and have multifunctional activities like protease, deubiquitinase, deISGylating and interferon antagonism. Therefore, PLpro is a promising target for drug and vaccine development.

Methods: T cells (MHCI & MHCII) and B cell (Discontinuous & Linear) epitopes of SARS COV-2 PLpro were forecasted via computational and immunoinformatics approaches that show a crucial part in promoting immune responses against COVID-19. Online tools were used to analyze the allergenicity, physiochemical properties, antigenicity and structural details of PLpro.

Results: Fifty-three Linear B-cell epitopes were identified, of which ‘KPLEFGATSAALQP’ and ‘EDDYQGKPLEFGAT’ had higher score and antigenicity. Antigenic, non-allergenic and conserved (T cell) epitopes whichwere bounded to multiple alleles were selected. In total, twelve epitopes were taken (6 MHC I and 6 MHC II).From MHC class I ‘YHTTDPSFLGRY’ and MHC class II ‘PFVMMSAPPAQYELK’ had more antigenicity among T cell epitopes. Furthermore, the protection and stability of peptides were tested through digestion analysis.

Conclusion: Predicted epitopes could be served as vaccine candidate to eliminate COVID-19. Even so, the presented epitopes required to be validated experimentally to check its safety and immunogenic profile

Keywords

Papain like protease, Digestion analysis, Allergenicity, Antigenicity

Papain like protease articles; Digestion analysis articles; Allergenicity articles; Antigenicity articles

Article Details

1. Introduction

Coronaviruses are positive-sense RNA viruses which are widely spread among humans and many other species of mammals [1]. Two types of coronaviruses such as SARS-CoV [2-4] and MERS-CoV [5, 6] cause infection and more than 10,000 cases have been reported in the past two decades. In December 2019, numerous incidences of an unknown cause of COVID-19 occurred in Wuhan, Hubei, China, with the clinical presentations closely similar to viral pneumonia [7]. The cause of the cases of pneumonia was reported as a novel beta coronavirus, SARS-CoV- 2.The genome of SARS-CoV-2 includes 3-chymotrypsin like protease (3CLpro), papain-like protease (PLpro), RNA-dependant-RNA polymerase andstructural proteins (spike glycoprotein, Envelope, membrane and nucleoprotein).Sequence analysis of SARS-CoV-2 revealed, receptor- binding domain(RBD) and receptor binding motif(RBM) together interact with the receptor angiotensin enzyme 2(ACE2)[8, 9].

SARS-CoV-2identified through deep sequence analysis and more than 800 cases reported in Wuhan and various cases reported in Japan, Thailand, South Korea and the USA. This novel coronavirus was discovered by NHC Key Laboratory of System Biology and Christophe Meraux, China that was confirmed by the WHO[10].WHO declared the public health risks about coronavirus in January 2020 and also gave information that there is no vaccine approved till now[9]. It is confirmed through phylogenetic analysis that the origin of Coronavirus is a bat that transmitted human to human by droplets/air. Infected persons have symptoms such as diarrhea, thrombocytopenia, fever, and respiratory disorders. Further analysis has been made by Real Time-PCR for the gene coding internal RNA-RNA dependent polymerase and Spike’s receptor- binding domain and these analyses after that conformed through Sanger Sequencing and full genome analysis is done by Next Generation Sequencing(NGS)[11-13].The mentioned nonstructural proteins such as PLpro, RNA-RNA dependent polymerase and chymotrypsin-like protease are conserved among all types of coronaviruses, therefore, these proteins could be used as strong antiviral targets to develop a vaccine against SARS and MERS[13].

At present time, no vaccine is availableto cure coronavirus infection in humans. Traditionally two medicines such as ShuFengJieDu and Lianhuaqingwen capsules are usedto treat COVID-19 in China [14]. Many other options could be used for the treatment of SARS-CoV-2 such as vaccines, peptides, monoclonal-oligonucleotides based therapies, and small molecule drugs but these preventive methods need months to years for the development [15].

The purpose of immunization is to design vaccines that have to initiate rapid immune response against pathogen’s antigen. In Vitro vaccine designing could be expensive,time exhausting and there is a need to culture the viruses which is not safe biologically[16]. In immunoinformatic,there is no need to culture viruses and it is biologically safe.B-cells and T- cells are important cells of the immune system that produce immune responses. Immunoinformatics is sub-field of bioinformatics that consist of many bioinformatics tools and databases. Immunological data prediction have been done with the help of these tools. In the advancement of tools, now it has been easy for the scientists to predict B-cell and T-cell epitopes [17] for the development of vaccine sub-unit construct [18, 19]. The basic mechanism to design the peptide vaccine is the prediction of the B-celland T-cell epitopes that are antigenic having particular immune-responses [20]. Therapeutic strategies for the treatment of the E-bola, Zika, and MERS-COV viruses have been designed by the use ofthe in silico peptide prediction approach in various studies [21-23]. The recent study was designed to predict epitopes from SARS-COV-2 PLpro which may be helpful to develop vaccine in future.

2. Methodology

2.1 Protein structure analysis/Physiochemical Properties prediction of PLpro

The protein sequence of PLpro was taken from Genbank(ID: QHD43415.1)[24]. To evaluate the chemical and physical properties of PLpro the Expasy ProtParam tool was used [25]. GOR4 was used to analyze the protein’s secondary structure. Protein’s transmembrane topology was analyzed usingthe TMHMM tool. Di-sulphide-bonds of the protein were forecasted by DIANNA v1.1[26]. Antigenicity and Allergenicity of protein werepredicted viaVAXIJEN & ALLERTOP servers [27, 28].

2.2 3D Structure Prediction& Validation

The tertiary structure of the PLpro was identified through different online tools like Phyre 2,Swissmodel, C-I tasser and Raptor x[29-31]. Galaxy refine server was used to refine the retrieved model [32]. The refined structure was then checked in PROSA web server that offers a quality factor. The quality-factor suggests a potential protein structure defect, beyond the usual range of native proteins [33]. Ramachandran plot was created with the PROCHECK principle via rampage server to validate the refined structure [34]. To evaluate the details of unbounded interactions, ERRAT server was used [35].

2.3 Prediction of B-cell epitopes

B-cell epitopes help in defending the immune-system. ABC-PRED was applied to identify B- cell epitopes with the threshold value of 0.51[36]. Epitopes visible on the surface were selected for antigenicity testing via VaxiJen server at 0.5 threshold. Kolaskar and Tongaonkar Antigenicity scale, Parkar hydrophilicity prediction algorithm, Karplus and Schulz flexibility prediction tool, Emini surface accessibility prediction method were applied to execute antigenicity, hydrophilicity, flexibility, surface accessibility analysis respectively [37]. As discontinuous epitopes have higher dominant properties than linear epitopes and are more evident.Discontinuous epitopes were identified through DiscoTope 2.0server using three- dimensional structure of PLpro protein [38]. Pymol was applied to visualize the location of epitopes on the 3D protein structure [39].

2.4 T-cell epitopes prediction

T-cell epitopes have avital role in designing of a vaccine. MHC-I &MHCII T cell epitopes were predicted through the IEDB database having a length of peptides 12 and 15 mer respectively[40].HLA alleles were chosen in large numbers so that epitope prediction should be accurate. For prediction, all the alleles were selected and the sequence was given in FASTA format. T-cell epitopes having lower ranking score which is less than 2.0 considered good binders and could be used for further research.

2.5 Conservation Analysis of Epitopes

Conservation analysis was done by the IEDB server database. Epitopes with 100% conservation were selected[41].

2.6 Population Coverage Estimation

The distribution and expression of HLA alleles dependupon the world’s regions and ethnicities, therefore impacting the efficient production of an epitope-based vaccine [42]. In this study selected MHC class I and MHC class II epitopes and related HLA alleles were used for population coverage analisis via IEDB population coverage tool [43]. Population coverage of each epitope was estimated in the regions where SARS-COV-2 cases were reported.

2.7 Properties Evaluation of Peptides

Expassy Protparam tool was applied to check the physiochemical properties of peptides like molecular weight and theoretical pI. VaxiJen v 2.0 and Allergen Fp 1.0 was used to forecast Antigenicity and Allergenicity of the peptide [44]. Toxic and non-toxic peptide prediction was done by ToxinPred but for further analysis, non-toxic peptide was selected [45]. To forecast peptide digester enzymes; the protein-digesting enzyme server was used.

2.8 Peptides Modeling and Docking

PEPFOLD was applied for the prediction of tertiary structures of six MHC I epitopes. PEPFOLD creates five models for each peptide and the best model was picked for further work [46]. 3D structure of the HLA –B7 allele was downloaded from PDB (ID: 3VCL).ClusPro (v.2) was used for molecular docking [47].

fortune-biomass-feedstock

3. Results

3.1 Sequence retrieval & structural analysis

ProtParam was used to evaluate physiochemical properties of SARS COV-2 PLpro. Protein is in stable form, acidic and hydrophilic and has molecular weight 217252.61 kDa. Antigenicity and allergenicity of this sequence weretested by AllerTop and VaxiJen respectively.The results indicate thenon-allergenic and antigenic nature of proteinhaving an antigenicity value of0.5142. DIANNA v1.1 was used to evaluate 51 disulphide bonds of protein (Additional file 1: Table S1). Four transmembrane helices were predicted through TMHMM. Residues of protein that were on transmembrane helix were from 1413-1435, 1500-1522, 1532-1554 and 1561-1583. Residues from 1-1412, 1523-1531 and 1584-1945 were found on the outer surface. Protein residues from 1436-1499 and 1555-1560 were found in the inner surface of the core region. GOR4was used to forecast the details of the secondary structure of the target protein. Among the 1945 amino acids, the formation of α-helix consists of 508 amino acids representing 26.12%, 472 in beta strands representing 24.27% and 965 amino acids forms coils representing 49.61% of the total protein composition.

3.2 Tertiary Structure Prediction and Validation

Models retrieved from the Swiss model, C-I Tasser, Raptor x and Phyre 2 were evaluated by Ramachandran plot analysis.The model retrieved from the Swiss Model was best compared to other resources.The protein homology model based on the quality of QMEAN was developed in the Swiss Model. It providesQMean value and GMQE(Global Model Quality Estimation) value.GMQE represents the certainty of a model considering the coverage, arrangement of the target and the template.Higher GMQE value represents a better quality of the model. It is usually measuredin the range of 0 and 1.GMQE of the model was 0.11 and QMean was -0.28 which indicates the high quality of the protein structure. The best template was found to be 3e9s having a sequence identity of 82.86%(Figure 1a).The model was then refined by the Galaxy refine server.The improved model has 98.1% favored region in RAMPAGE and poor rotamers as 0.4%, qrmsd as 0.298, clash score as 10.6, MolProbity as 1.542(Figure 1c). ProSA-web also gives−9.02 Z, which is within an acceptable range (Figure 1b). These results show that the refined model has goodquality.

fortune-biomass-feedstock

Figure 1: (a) 3D structural representation of PLpro protein predicted by Swiss Model (b) the z- score (-9.02) of the PLproprotein; (c) the Ramachandran plot of refined structure shows 98.1, 1.9% and 0.0% residues in favored, allowed and disallowed region, respectively.

3.3 B cell epitopes prediction

B cell epitope of target protein was checked by ABCpred and TMHMM server were used to check surface availabity. VaxiJen was used to find the antigenicity of the epitopes. Epitopes that were 100% conserved, evident on the surface and antigenic were picked. A Total of 53 epitopes was chosen. ‘KPLEFGATSAALQP’ and ‘EDDYQGKPLEFGAT’ had high Antigenicity (1.7) and score(Table 1). We used Pymol to visualize the position of epitopes on the protein(Figure 2). Besides, surface accessibility of B cell epitopes was assessed. Through observing their concentration in previously identified B cell epitopes and physiochemical properties, the target protein was evaluatedfor prediction of B cell epitopes by Kolaskar and Tongaonkar antigenicity tool.Window size and a threshold werekept at 7 and 1.045 respectively. The antigenic propensity value of PLpro was predicted as 1.041 Average, 0.859 Minimum and 1.258 Maximum(Figure 3A).Experimental research reveals that antibodies or alleles binding section of epitopes is elastic. Hydrophilic protein areas have a role in triggering an immune response and usually have surface exposure.Vaxijen antigenic value and the ABCpred score indicate that all predicted epitopes belong to the extracellular area of transmembrane proteins, which might boost a host defensive reaction during SARS-COV-2 infection. The parker hydrophilicity prediction algorithm with a threshold of 1.279 was used to evaluate hydrophilicity.Values calculated by parker hydrophilicity were 1.409Average, -8.971 Minimum and 8.129 Maximum(Figure 3C). Emini surface accessibility prediction method with a threshold of 1.009 was used to calculate the surface abundance of potential B cell epitopes. Additional file 2 (Table S2)contains the findings of the Emini surface accessibility(Figure 3D). Chou and Fasman beta-turn analyzing algorithm was used for the prediction of beta-turn because beta-turns play a vital role in initiating the defensive response. Beta-turns are hydrophilic and exposed to the surface. It calculated the values of 0.973Average, 0.593Minimum and 1.414 Maximum at the threshold of 1.009. The results show that the area from 1098-1104 amino acids and 1849-1855 amino acids are more likely to persuade beta turns in peptide structure(Figure 3B).Flexibility analysis by Karplus and schulz tool showed that the area from673-679 amino acids is highly versatile (Figure 3E).

DiscoTope 2.0 server was applied to trackthe surface abundance of residual contact numbers and use the novel amino acid score to preview discontinuous epitopes to further improve the specificity and variety of B cell epitopes.At − 3.700 threshold, 22.000 Angstroms propensity score radius and 90% specificity, twenty-nine discontinuous epitopes were identified from the 3D structure of the protein(Table 2). Pymol visualized the location of epitopes on the 3D protein structure(Figure 4).

Table 1: Emini Surface accessibility of PLpro predicted by EMINI surface accessibility tool

Table icon
fortune-biomass-feedstock

Figure 2: Specific sites of B cells predicted linear epitopes on the 3D structure of PLpro Protein

fortune-biomass-feedstock

Figure 3: (A) Prediction of antigenic determinants of PLpro protein using Kolaskar and Tongaonkar Antigenicity Scale; (B) Beta turns analyses in PLpro protein using Chou and Fasman Beta Turn Prediction; (C) Hydrophilicity Prediction of using PLpro protein Parker Hydrophilicity; (D) Surface Accessibility Analyses of PLpro protein using Emini Surface Accessibility Scale; (E) Flexibility Analyses of PLpro protein using Karplus and Schulz Flexibility Scale.

fortune-biomass-feedstock

Figure 4: Specific sites of B cells discontinuous epitopes predicted through DISCOTOPE 2.0 server on the 3D structure of PLpro protein

Table 2: Discontinuous epitopes predicted through DiscoTop 2.0 server

Residues Position

Residues Name

Number of Contacts

Propensity Score

Discotop Score

746

GLU

4

2.165

1.456

747

VAL

3

1.617

1.086

748

ARG

12

1.266

-0.26

749

THR

8

0.303

-0.652

750

ILE

19

-0.128

-2.378

751

LYS

3

-0.5

-0.788

763

THR

3

-3.163

-3.144

765

VAL

3

-0.715

-0.977

767

ASP

10

0.338

-0.85

768

MET

12

1.024

-0.474

769

SER

3

1.2

0.717

770

MET

9

1.122

-0.042

771

THR

13

0.48

-1.07

773

GLY

10

-0.637

-1.714

774

GLN

11

0.154

-1.129

775

GLN

26

-0.562

-3.487

787

THR

10

-1.994

-2.915

788

LYS

2

-0.051

-0.275

789

ILE

11

0.306

-0.994

790

LYS

8

0.659

-0.337

791

PRO

28

0.942

-2.386

792

HIS

10

1.274

-0.023

793

ASN

3

1.662

1.126

794

SER

5

1.496

0.749

795

HIS

29

0.839

-2.539

796

GLU

5

-0.023

-0.059

797

GLY

1

-0.103

-1.012

806

ASP

8

-2.763

-3.366

807

ASP

0

-2.535

-2.244

3.4 T cell epitopes prediction and properties evaluation

IEDB consensus method was used to forecast T-cell MHC Class-I as well as MHC class-II epitopes. Peptides due to strong defensive ability can be bind to multiple alleles therefore; this peptide is considered most appropriate. Their Allergenicity and Antigenicity were checked by Allergen FP 1.0 and VaxiJen respectively and IEDB conservancy tool was used for their conservation analysis of protein sequence. Epitopes that are 100% conserved, highly antigenic, non-allergenicand bound to multiple alleles were screened out. 6 MHC-class-I and 6 MHC class- II alleles were shortlisted. Between MHC class-I epitopes ‘YHTTDPSFLGRY’ has the highest antigenicity (1.3) binding with multiple alleles including HLA-A*01:01HLA-A*26:01, HLA- A*29:02, HLA-A*30:02, HLA-A*25:01, HLA-B*38:01, HLA-A*68:01(Table 3). In MHC class-II epitopes ‘PFVMMSAPPAQYELK’ had higher Antigenicity score(0.8) binding with multiple alleles HLA-DRB1*01:02, HLA-DRB1*09:01, HLA-DRB1*01:01, HLA-DRB1*13:07, HLA-DRB1*04:08, HLA-DRB1*11:07, HLA-DRB1*11:14, HLA-DRB1*13:23, HLA-DRB1*03:05 (Table 4). To estimate peptide digesting enzymes, the protein digesting enzyme server was used. The enzymes that do not digest peptide into fragments is considered a non- digestive enzyme. Peptides that are digestible with multiple enzymes are not stable. Peptides that are digested with fewer enzymes are considered most stable and favorable for vaccine (Table 5).

Table 3: MHC class I binding peptides with their antigenicity score

Peptide(position)

Alleles

Antigenicity

MHC Class 1

YHTTDPSFLGRY(25-36)

HLA-A*01:01, HLA-A*26:01,HLA-A*29:02 HLA-A*30:02, HLA-A*25:01, HLA-B*38:01 HLA-A*68:01

1.3

ETISLAGSYKDW (33-44)

HLA-A*25:01, HLA-A*26:01, HLA-B*57:01 HLA-B*58:01, HLA-A*68:01

0.8

FGLVAEWFLAYI(11-22)

HLA-A*26:01, HLA-A*25:01, HLA-A*29:02 HLA-B*35:01, HLA-A*01:01, HLA-C*08:02 HLA-A*02:01, HLA-B*46:01, HLA-B*15:02 HLA-A*68:02 , HLA-C*12:03

0.5

GVVDYGARFYFY(14-25)

HLA-A*29:02, HLA-A*01:01, HLA-C*05:01 HLA-A*30:02, HLA-A*26:01, HLA-A*11:01 HLA-A*23:01

0.7

DLTAFGLVAEWF(7-18)

HLA-B*46:01, HLA-B*57:01

0.6

YYSQLMCQPILL(40-51)

HLA-A*02:01, HLA-A*24:02, HLA-C*14:02 HLA-C*07:02, HLA-B*48:01, HLA-A*23:01 HLA-B*38:01

Table 4: MHC class II binding peptides with their antigenicity score

Peptide(position)

Alleles

Antigenicity

MHC Class 2

SPFVMMSAPPAQYEL(52-66)

HLA-DRB1*01:01,HLA DRB1*01:02,HLA-

DRB1*09:01,

HLA-DRB1*13:07,HLA DRB1*04:08,HLA-DRB1*11:07,HLA- DRB1*11:14,HLA-DRB1*13:23, HLA-DRB1*03:05HLA-DRB1*04:04,HLA-DRB1*08:02

0.5

KSAFYILPSIISNEK(20-34)

HLA-DRB1*04:08,

HLA-DRB1*04:26,

HLA-DRB1*01:01,HLA-DRB1*11:01, HLA-DRB1*04:21, HLA-DRB1*11:28,HLA-DRB1*13:05,

HLA-DRB1*13:07,HLA-DRB1*04:01,HLA-DRB1*13:21

0.7

SAFYILPSIISNEKQ(21-35)

DRB1*13:07,HLA-DRB1*04:01,HLA-DRB1*13:21
HLA-DRB1*04:08,HLA-DRB1*04:26,

HLA-DRB1*11:01,HLA-DRB1*04:21, HLA-DRB1*11:28, HLA-DRB1*13:05,HLA-DRB1*01:01, HLA- DRB1*13:07, HLA-DRB1*04:01,HLA-DRB1*13:21

0.6

EVITFDNLKTLLSLR(9-23)

HLA-DRB1*04:01,

HLA-DRB1*15:06,

HLA-DRB1*04:04

0.5

PFVMMSAPPAQYELK(53-67)

HLA-DRB1*01:02,

HLA-DRB1*09:01,

HLA-DRB1*01:01,HLA-DRB1*13:07, HLA-DRB1*04:08, HLA-DRB1*11:07,HLA-DRB1*11:14, HLA- DRB1*13:23, HLA-DRB1*03:05,HLA-DRB1*08:02

0.8

QQESPFVMMSAPPAQ(49-63)

HLA-DRB1*01:02,

HLA-DRB1*01:01,

HLA-DRB1*09:01,HLA-DRB1*13:07, HLA-DRB1*04:08, HLA-DRB1*11:07,HLA-DRB1*11:14,

HLA-DRB1*13:23,HLA-DRB1*03:05,HLA-DRB1*08:02

0.6

Table 5: Peptides that are digested with fewer enzymes are considered most stable and favorable for vaccine.

Table icon

3.5 Population coverage of Peptides

Population coverage was foundforthe selectedsix MHC class-I and six MHC class-II epitopes and related alleles. Epitopes that were selected represent 94.70% and 44.02% of total world population respectively. Highest population coverage of MHC class-I epitopes was found in Germany (97.14 %) and MHC class -II epitopes was found in Sweden (67.80%).SARS-COV-2 MHC class -I epitopes displayed 91.28 % and MHC class -II exhibited 28.71% population coverage in China. Population coverage was higher in those regions where SARS-COV-2 cases were reported (Figure 5).

fortune-biomass-feedstock

Figure 5: a) Population Coverage of MHC class I and MHC class II around the globe predicted by IEDB population Coverage Tool

3.6 Molecular Docking

3D structures of selected six MHC class I epitopes were forecasted using PEPFOLD (Figure 6). Molecular docking is necessary to understand the pattern of interaction between protein and peptide. By performing molecular docking the interaction of HLA allele with selected MHC class I epitope was analyzed. To analyze the interaction between allele and peptides, ClusPro (v.2) webserver was used. Rigid docking was performed by the server by sampling billions of conformations, energy minimization and RMSD of the complex [47]. Pymol was used to visualize the docked complexes. Docking results revealed the strong interactions among all selected peptides inside the receptor binding site of HLA allele (Figure 7).

fortune-biomass-feedstock

Figure 6: 3D structures of MHC Class I peptides predicted by PEPFOLD.

fortune-biomass-feedstock

Figure 7: The 3D binding pattern of the selected 6 peptides (red) docked with HLA-B7 allele (blue).

4. Discussion

Several viral infections appeared through many fatal new viruses and these viruses are disastrous for humans. Therefore, vaccine designing to tackle viruses is difficult in a short period [48]. One of the most dangerous infectious viruses such as the 2019 novel coronavirus also called SARS- CoV-2 identified (10 February 2020) in patients of severe pneumonia in Wuhan (China)[15]. Several methods could be used for the treatment of coronavirus such as vaccine, peptides, monoclonal antibodies but we designed peptides for SARS-CoV-2. Genome analysis of 2019- nCoV reveals that four catalytic sites are conserved among all kinds of coronaviruses therefore it is suggested to redesign the already present inhibitors of MERS and SARS[8]. Genomic RNA of SARS-CoV is replicated with the help of replicasepolyproteins that are activated with the help of two enzyme proteases such as 3C-like protease (3CLpro) and Papain like protease (PLpro)[49]. SARS-CoVPLpro replicates the polyprotein by the conserved cleavage sites that are conserved among coronaviruses. Furthermore, it is suggested that aspartic acid (ASP1826) and four cysteine residues are essential to perform the activity of PLpro in SARS-CoV[50]. The vaccine could be beneficial and cost-effective in preventing the viral attack but biologically it takes years to be designed in active form. So at presentimmunoinformatics is used to make peptide-based vaccine which is biologically safe and designed in less time than in-vitro vaccine [51].With the advancement in bioinformatics techniques such as next-generation sequencing(NGS) and proteomics enables us to design effective vaccine bases on peptide through the computational immunology (Immunoinformatics)[52, 53].

The development of the peptide based vaccine was explored in this study targeting the papain- like protease protein of the SARS-COV-2. Primary, secondary, and tertiary structure levels of the protein were analyzed. The primary structure of the protein was analyzed by protparam which indicates that protein was 217252.61 kDa in molecular weight. Protein was acidic according to its theoretical PI value. The calculated aliphatic index and instability index values showed the thermostability and stability of the protein. A negative score of the grand average of hydropathy indicates the hydrophilic nature that renders its interaction with neighboring water molecules. Protein was found to be antigenic, immunogenic and non-allergenic indicating the potential to cause robust immune response without any allergic reactions.

B & T cell epitopes of the target protein were forecasted to assist the immune response of the host.Forecasting T cell &B cell is an important step in vaccine development; therefore both types of epitopes were predicted by the protein sequence and their antigenicity was assessed. ABCpred and Discotope 2.0 servers were used to predict linear and discontinuous B cell epitopes respectively. Different IEDB techniques were used to access solvent accessibility, antigenicity, disulphide bonds, and flexibility. B cell epitopes that were antigenic and present on the outer surface were considered. ‘KPLEFGATSAALQP’ and ‘EDDYQGKPLEFGAT’ had high antigenicity (1.7) and score among B cells. Furthermore, the IEDB consensus approach predicts antigenic T cell determinants with the ability to bind MHC class I and MHC class II. Antigenic, non-allergenic and conserved T cell epitopes that were bound to multiple alleles were considered. YHTTDPSFLGRY’ in MHC class I and ‘PFVMMSAPPAQYELK’ in MHC class II had the highest antigenicity among T cell epitopes. Pymol visualized the location of peptides on the 3D protein structure. Vaccine’s efficacy depends on the population in which the vaccine is being used. MHC class I and MHC class II epitopes that were selected represent 94.70% and 44.02% of the world’s population respectively, indicating vaccine developed would be effective for most of the world population. Allergenicity, toxicity and physiochemical properties of predicted epitopes have also been tested for further improvement in specificity and selection. Digestion analysis tests peptideprotection and stability.Epitopes identified during analysis should be tested for the therapeutic potential for futures studies.

5. Conclusion

A reverse vaccinology approach was implemented in this study to recognize surface-exposed peptides, instead of concentrating on the entire pathogen, an inefficient and effective procedure. B-cells& T-cell epitopes predictedby sequence, conservational, andstructure analysis. B-cell and T- cell epitopes now become vital research due to their predictability, speed, low cost and efficiency. The epitopes with higher antigenicity were selected and these selected peptides would be helpful todesign vaccine against the SARS-COV-2 virus.

References

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395 (2020): 497-506.
  2. Richman DD, Whitley RJ, Hayden FG. Clinical virology: John Wiley & Sons (2016).
  3. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. New England journal of medicine 348 (2003): 1953-1966.
  4. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine 348 (2003): 1967-1976.
  5. De Groot RJ, Baker SC, Baric RS, et al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. Journal of virology 87 (2013): 7790-7792.
  6. Zaki AM, Van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine 367 (2012): 1814-1820.
  7. xinhuanet.com. [updated 2020-01-23]. Available from: (http://www.xinhuanet.com/english/2020-01/23/c_138728428.htm). .
  8. De Clercq EJCAAJ. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J 14 (2019): 3962-3968.
  9. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91 (2020): 264-266.
  10. Haynes B, Messonnier NE, Cetron MS. First travel-related case of 2019 novel coronavirus detected in United States: press release (2020): 639-3286.
  11. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395 (2020): 514-523.
  12. Luo G, Gao SJ. Global health concern stirred by emerging viral infections. J Med Virol 92 (2020): 399–400.
  13. Zumla A, Chan JF, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15 (2016): 327.
  14. Lu HJBt. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14 (2020): 69-71.
  15. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group 19 (2020): 149-150.
  16. Lo Y-T, Pai T-W, Wu W-K, et al. Prediction of conformational epitopes with the use of a knowledge-based energy function and geometrically related neighboring residue characteristics. BMC Bioinformatics 14 (2013): 3.
  17. Yang X, Yu XJ. An introduction to epitope prediction methods and software. Rev Med Virol 19 (2009): 77- 96.
  18. De Gregorio E, Rappuoli R. Vaccines for the future: learning from human immunology. Microb Biotechnol 5 (2012): 149-155.
  19. Patronov A, Doytchinova IJOb. T-cell epitope vaccine design by immunoinformatics. Open Biol 3 (2013): 120139.
  20. Abdelmageed MI, Abdelmoneim AH, Mustafa MI, et al. Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach. Biomed Res Int 2020 (2020).
  21. Ahmad B, Ashfaq UA, Rahman M-u, et al. Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: an immuno-informatics approach. Microbial pathogenesis 132 (2019): 243-253.
  22. Ashfaq UA, Ahmed B. De novo structural modeling and conserved epitopes prediction of Zika virus envelop protein for vaccine development. Viral immunology 29 (2016): 436-443.
  23. Ul Qamar MT, Saleem S, Ashfaq UA, et al. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune- informatics study. Journal of translational medicine 17 (2019): 362.
  24. Benson DA, Karsch-Mizrachi I, Lipman DJ, et al. GenBank. Nucleic acids research 37 (2008): 26-31.
  25. Gasteiger E, Gattiker A, Hoogland C, et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic acids research 31 (2003): 3784-3788.
  26. Ferrè F, Clote P. DiANNA 1.1: an extension of the DiANNA web server for ternary cysteine classification. Nucleic acids research 34 (2006): 182-185.
  27. Dimitrov I, Flower DR, Doytchinova I, et al. AllerTOP-a server for in silico prediction of allergens. BMC bioinformatics 20 (2013).
  28. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC bioinformatics 8 (2007): 4.
  29. Peng J, Xu J. RaptorX: exploiting structure information for protein alignment by statistical inference. Proteins: Structure, Function, and Bioinformatics. Proteins 79 (2011): 161-171.
  30. Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic acids research 46 (2018): 296- 303.
  31. Kelley LA, Mezulis S, Yates CM, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nature protocols 10 (2015): 845.
  32. Shin W-H, Lee GR, Heo L, et al. Prediction of protein structure and interaction by GALAXY protein modeling programs. Bio Design 2 (2014): 1-11.
  33. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic acids research 35 (2007): 407-410.
  34. Lovell SC, Davis IW, Arendall III WB, et al. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins: Structure, Function, and Bioinformatics 50 (2003): 437-450.
  35. Gundampati RK, Chikati R, Kumari M, et al. Protein- protein docking on molecular models of Aspergillus niger RNase and human actin: novel target for anticancer therapeutics. J Mol Model 18 (2012): 653-662.
  36. Saha S, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins: Structure, Function, and Bioinformatics. J Mol Model 65 (2006): 40-48.
  37. Jespersen MC, Peters B, Nielsen M, et al. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic acids research 45 (2017): 24-29.
  38. Sun P, Ju H, Liu Z, et al. Bioinformatics resources and tools for conformational B-cell epitope prediction. Computational and mathematical methods in medicine. Comput Math Methods Med 2013 (2013).
  39. DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystallography. CCP4 Newsletter Pro. Crystallogr 40 (2002): 82-92.
  40. Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC bioinformatics 11 (2010): 568.
  41. Bui H-H, Sidney J, Li W, et al. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC bioinformatics 8 (2007): 361.
  42. Adhikari UK, Tayebi M, Rahman MM. Immunoinformatics approach for epitope-based peptide vaccine design and active site prediction against polyprotein of emerging oropouche virus. Journal of immunology research 2018 (2018).
  43. Bui H-H, Sidney J, Dinh K, et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC bioinformatics 7 (2006): 153.
  44. Dimitrov I, Naneva L, Doytchinova I, et al. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics 30 (2014): 846-851.
  45. Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PloS one 8 (2013).
  46. Lamiable A, Thévenet P, Rey J, et al. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic acids research 44 (2016): 449-454.
  47. Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein–protein docking. Nature protocols 12 (2017): 255.
  48. Adhikari UK, Tayebi M, Rahman MM. Immunoinformatics approach for epitope-based peptide vaccine design and active site prediction against polyprotein of emerging oropouche virus. Journal of Immunology Research 2018 (2018): 1-22
  49. Baker SC, Shieh C, Soe LH, et al. Identification of a domain required for autoproteolytic cleavage of murine coronavirus gene A polyprotein. J Virol 63 (1989): 3693-3699.
  50. Goldsmith CS, Tatti KM, Ksiazek TG, et al. Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis 10 (2004): 320–326.
  51. María R, Arturo C, Alicia JA, et al. The impact of bioinformatics on vaccine design and development: InTech, Rijeka, Croatia (2017).
  52. Groot ASD, Rappuoli RJErov. Genome-derived vaccines. Expert Rev Vaccines 3 (2004): 59-76.
  53. De Groot AS. Immunome-derived vaccines. Taylor & Francis 4 (2004): 767-772.

Supplementary Materials

Table S1: Disulphide bonds of PLpro predicted by DIANNA v 1.1

Cysteine sequence position

Distance

Bond

Score

39 - 55

16

VLNEKCSAYTV-VNEFACVVADA

0.01058

39 - 104

65

VLNEKCSAYTV-ASHMYCSFYPP

0.03525

39 - 118

79

VLNEKCSAYTV-EEEGDCEEEEF

0.01323

39 - 285

246

VLNEKCSAYTV-KVGGSCVLSGH

0.0104

39 - 296

257

VLNEKCSAYTV-NLAKHCLHVVG

0.01043

39 - 347

308

VLNEKCSAYTV-HSLRVCVDTVR

0.01101

39 - 417

378

VLNEKCSAYTV-KKIKACVEEVT

0.01055

39 - 531

492

VLNEKCSAYTV-TVLKKCKSAFY

0.01039

39 - 574

535

VLNEKCSAYTV-KLMPVCVETKA

0.01042

39 - 856

817

VLNEKCSAYTV-WADNNCYLATA

0.0104

39 - 893

854

VLNEKCSAYTV-EAANFCALILA

0.01054

39 - 900

861

VLNEKCSAYTV-LILAYCNKTVG

0.0345

39 - 926

887

VLNEKCSAYTV-ANLDSCKRVLN

0.01045

39 - 934

895

VLNEKCSAYTV-VLNVVCKTCGQ

0.0104

39 - 937

898

VLNEKCSAYTV-VVCKTCGQQQT

0.86264

39 - 969

930

VLNEKCSAYTV-GVQIPCTCGKQ

0.0104

39 - 971

932

VLNEKCSAYTV-QIPCTCGKQAT

0.01043

39 - 1005

966

VLNEKCSAYTV-HGTFTCASEYT

0.01662

39 - 1015

976

VLNEKCSAYTV-TGNYQCGHYKH

0.01051

39 - 1029

990

VLNEKCSAYTV-KETLYCIDGAL

0.01066

39 - 1071

1032

VLNEKCSAYTV-LDGVVCTEIDP

0.01513

39 - 1114

1075

VLNEKCSAYTV-NFKFVCDNIKF

0.01067

39 - 1191

1152

VLNEKCSAYTV-KPNTWCIRCLW

0.01048

39 - 1194

1155

VLNEKCSAYTV-TWCIRCLWSTK

0.03167

39 - 1223

1184

VLNEKCSAYTV-MDNLACEDLKP

0.01079

39 - 1246

1207

VLNEKCSAYTV-KDVLECNVKTT

0.01381

39 - 1342

1303

VLNEKCSAYTV-NIVTRCLNRVC

0.01037

39 - 1347

1308

VLNEKCSAYTV-CLNRVCTNYMP

0.01037

39 - 1362

1323

VLNEKCSAYTV-LLLQLCTFTRS

0.01038

39 - 1392

1353

VLNEKCSAYTV-SVGKFCLEASF

0.01037

39 - 1421

1382

VLNEKCSAYTV-LLLSVCLGSLI

0.01037

39 - 1445

1406

VLNEKCSAYTV-GMPSYCTGYRE

0.01038

39 - 1464

1425

VLNEKCSAYTV-TIATYCTGSIP

0.9982

39 - 1470

1431

VLNEKCSAYTV-TGSIPCSVCLS

0.02564

39 - 1473

1434

VLNEKCSAYTV-IPCSVCLSGLD

0.02302

39 - 1586

1547

VLNEKCSAYTV-HVVDGCNSSTC

0.01615

39 - 1591

1552

VLNEKCSAYTV-CNSSTCMMCYK

0.01084

39 - 1594

1555

VLNEKCSAYTV-STCMMCYKRNR

0.03241

39 - 1605

1566

VLNEKCSAYTV-ATRVECTTIVN

0.01042

39 - 1627

1588

VLNEKCSAYTV-GGKGFCKLHNW

0.01072

39 - 1634

1595

VLNEKCSAYTV-LHNWNCVNCDT

0.06308

39 - 1637

1598

VLNEKCSAYTV-WNCVNCDTFCA

0.0146

39 - 1641

1602

VLNEKCSAYTV-NCDTFCAGSTF

0.01845

39 - 1731

1692

VLNEKCSAYTV-DGKSKCEESSA

0.0104

39 - 1748

1709

VLNEKCSAYTV-YSQLMCQPILL

0.01074

39 - 1836

1797

VLNEKCSAYTV-KDVVECLKLSH

0.01049

39 - 1852

1813

VLNEKCSAYTV-VTGDSCNNYML

0.01474

39 - 1873

1834

VLNEKCSAYTV-RDLGACIDCSA

0.01037

39 - 1876

1837

VLNEKCSAYTV-GACIDCSARHI

0.0229

39 - 1926

1887

VLNEKCSAYTV-PFKLTCATTRQ

0.01038

55 - 104

49

VNEFACVVADA-ASHMYCSFYPP

0.01125

55 - 118

63

VNEFACVVADA-EEEGDCEEEEF

0.03137

55 - 285

230

VNEFACVVADA-KVGGSCVLSGH

0.01051

55 - 296

241

VNEFACVVADA-NLAKHCLHVVG

0.01039

55 - 347

292

VNEFACVVADA-HSLRVCVDTVR

0.01046

55 - 417

362

VNEFACVVADA-KKIKACVEEVT

0.01073

55 - 531

476

VNEFACVVADA-TVLKKCKSAFY

0.01069

55 - 574

519

VNEFACVVADA-KLMPVCVETKA

0.01113

55 - 856

801

VNEFACVVADA-WADNNCYLATA

0.01164

55 - 893

838

VNEFACVVADA-EAANFCALILA

0.0104

55 - 900

845

VNEFACVVADA-LILAYCNKTVG

0.01049

55 - 926

871

VNEFACVVADA-ANLDSCKRVLN

0.01047

55 - 934

879

VNEFACVVADA-VLNVVCKTCGQ

0.01059

55 - 937

882

VNEFACVVADA-VVCKTCGQQQT

0.01414

55 - 969

914

VNEFACVVADA-GVQIPCTCGKQ

0.01045

55 - 971

916

VNEFACVVADA-QIPCTCGKQAT

0.0109

55 - 1005

950

VNEFACVVADA-HGTFTCASEYT

0.0132

55 - 1015

960

VNEFACVVADA-TGNYQCGHYKH

0.02341

55 - 1029

974

VNEFACVVADA-KETLYCIDGAL

0.01089

55 - 1071

1016

VNEFACVVADA-LDGVVCTEIDP

0.01213

55 - 1114

1059

VNEFACVVADA-NFKFVCDNIKF

0.01347

55 - 1191

1136

VNEFACVVADA-KPNTWCIRCLW

0.01041

55 - 1194

1139

VNEFACVVADA-TWCIRCLWSTK

0.01044

55 - 1223

1168

VNEFACVVADA-MDNLACEDLKP

0.01052

55 - 1246

1191

VNEFACVVADA-KDVLECNVKTT

0.01056

55 - 1342

1287

VNEFACVVADA-NIVTRCLNRVC

0.01038

55 - 1347

1292

VNEFACVVADA-CLNRVCTNYMP

0.01037

55 - 1362

1307

VNEFACVVADA-LLLQLCTFTRS

0.24573

55 - 1392

1337

VNEFACVVADA-SVGKFCLEASF

0.01041

55 - 1421

1366

VNEFACVVADA-LLLSVCLGSLI

0.01384

55 - 1445

1390

VNEFACVVADA-GMPSYCTGYRE

0.01047

55 - 1464

1409

VNEFACVVADA-TIATYCTGSIP

0.01861

55 - 1470

1415

VNEFACVVADA-TGSIPCSVCLS

0.03859

55 - 1473

1418

VNEFACVVADA-IPCSVCLSGLD

0.01047

55 - 1586

1531

VNEFACVVADA-HVVDGCNSSTC

0.01054

55 - 1591

1536

VNEFACVVADA-CNSSTCMMCYK

0.01043

55 - 1594

1539

VNEFACVVADA-STCMMCYKRNR

0.01251

55 - 1605

1550

VNEFACVVADA-ATRVECTTIVN

0.01037

55 - 1627

1572

VNEFACVVADA-GGKGFCKLHNW

0.01146

55 - 1634

1579

VNEFACVVADA-LHNWNCVNCDT

0.01066

55 - 1637

1582

VNEFACVVADA-WNCVNCDTFCA

0.01171

55 - 1641

1586

VNEFACVVADA-NCDTFCAGSTF

0.99999

55 - 1731

1676

VNEFACVVADA-DGKSKCEESSA

0.01042

55 - 1748

1693

VNEFACVVADA-YSQLMCQPILL

0.02261

55 - 1836

1781

VNEFACVVADA-KDVVECLKLSH

0.01049

55 - 1852

1797

VNEFACVVADA-VTGDSCNNYML

0.82462

55 - 1873

1818

VNEFACVVADA-RDLGACIDCSA

0.01037

55 - 1876

1821

VNEFACVVADA-GACIDCSARHI

0.01106

55 - 1926

1871

VNEFACVVADA-PFKLTCATTRQ

0.01038

104 - 118

14

ASHMYCSFYPP-EEEGDCEEEEF

0.01038

104 - 285

181

ASHMYCSFYPP-KVGGSCVLSGH

0.01148

104 - 296

192

ASHMYCSFYPP-NLAKHCLHVVG

0.01038

104 - 347

243

ASHMYCSFYPP-HSLRVCVDTVR

0.01189

104 - 417

313

ASHMYCSFYPP-KKIKACVEEVT

0.01037

104 - 531

427

ASHMYCSFYPP-TVLKKCKSAFY

0.01037

104 - 574

470

ASHMYCSFYPP-KLMPVCVETKA

0.01037

104 - 856

752

ASHMYCSFYPP-WADNNCYLATA

0.01079

104 - 893

789

ASHMYCSFYPP-EAANFCALILA

0.01038

104 - 900

796

ASHMYCSFYPP-LILAYCNKTVG

0.01236

104 - 926

822

ASHMYCSFYPP-ANLDSCKRVLN

0.01037

104 - 934

830

ASHMYCSFYPP-VLNVVCKTCGQ

0.01037

104 - 937

833

ASHMYCSFYPP-VVCKTCGQQQT

0.01122

104 - 969

865

ASHMYCSFYPP-GVQIPCTCGKQ

0.01038

104 - 971

867

ASHMYCSFYPP-QIPCTCGKQAT

0.01037

104 - 1005

901

ASHMYCSFYPP-HGTFTCASEYT

0.0106

104 - 1015

911

ASHMYCSFYPP-TGNYQCGHYKH

0.01172

104 - 1029

925

ASHMYCSFYPP-KETLYCIDGAL

0.01037

104 - 1071

967

ASHMYCSFYPP-LDGVVCTEIDP

0.01429

104 - 1114

1010

ASHMYCSFYPP-NFKFVCDNIKF

0.01049

104 - 1191

1087

ASHMYCSFYPP-KPNTWCIRCLW

0.01052

104 - 1194

1090

ASHMYCSFYPP-TWCIRCLWSTK

0.02164

104 - 1223

1119

ASHMYCSFYPP-MDNLACEDLKP

0.01041

104 - 1246

1142

ASHMYCSFYPP-KDVLECNVKTT

0.01208

104 - 1342

1238

ASHMYCSFYPP-NIVTRCLNRVC

0.01038

104 - 1347

1243

ASHMYCSFYPP-CLNRVCTNYMP

0.01037

104 - 1362

1258

ASHMYCSFYPP-LLLQLCTFTRS

0.01039

104 - 1392

1288

ASHMYCSFYPP-SVGKFCLEASF

0.01037

104 - 1421

1317

ASHMYCSFYPP-LLLSVCLGSLI

0.01037

104 - 1445

1341

ASHMYCSFYPP-GMPSYCTGYRE

0.01038

104 - 1464

1360

ASHMYCSFYPP-TIATYCTGSIP

0.84832

104 - 1470

1366

ASHMYCSFYPP-TGSIPCSVCLS

0.01055

104 - 1473

1369

ASHMYCSFYPP-IPCSVCLSGLD

0.01088

104 - 1586

1482

ASHMYCSFYPP-HVVDGCNSSTC

0.01065

104 - 1591

1487

ASHMYCSFYPP-CNSSTCMMCYK

0.01037

104 - 1594

1490

ASHMYCSFYPP-STCMMCYKRNR

0.02433

104 - 1605

1501

ASHMYCSFYPP-ATRVECTTIVN

0.01129

104 - 1627

1523

ASHMYCSFYPP-GGKGFCKLHNW

0.63807

104 - 1634

1530

ASHMYCSFYPP-LHNWNCVNCDT

0.01115

104 - 1637

1533

ASHMYCSFYPP-WNCVNCDTFCA

0.01117

104 - 1641

1537

ASHMYCSFYPP-NCDTFCAGSTF

0.01041

104 - 1731

1627

ASHMYCSFYPP-DGKSKCEESSA

0.01038

104 - 1748

1644

ASHMYCSFYPP-YSQLMCQPILL

0.01051

104 - 1836

1732

ASHMYCSFYPP-KDVVECLKLSH

0.01037

104 - 1852

1748

ASHMYCSFYPP-VTGDSCNNYML

0.01053

104 - 1873

1769

ASHMYCSFYPP-RDLGACIDCSA

0.01037

104 - 1876

1772

ASHMYCSFYPP-GACIDCSARHI

0.0113

104 - 1926

1822

ASHMYCSFYPP-PFKLTCATTRQ

0.01037

118 - 285

167

EEEGDCEEEEF-KVGGSCVLSGH

0.0104

118 - 296

178

EEEGDCEEEEF-NLAKHCLHVVG

0.01038

118 - 347

229

EEEGDCEEEEF-HSLRVCVDTVR

0.01037

118 - 417

299

EEEGDCEEEEF-KKIKACVEEVT

0.01044

118 - 531

413

EEEGDCEEEEF-TVLKKCKSAFY

0.0104

118 - 574

456

EEEGDCEEEEF-KLMPVCVETKA

0.01038

118 - 856

738

EEEGDCEEEEF-WADNNCYLATA

0.01063

118 - 893

775

EEEGDCEEEEF-EAANFCALILA

0.01037

118 - 900

782

EEEGDCEEEEF-LILAYCNKTVG

0.01037

118 - 926

808

EEEGDCEEEEF-ANLDSCKRVLN

0.01037

118 - 934

816

EEEGDCEEEEF-VLNVVCKTCGQ

0.01037

118 - 937

819

EEEGDCEEEEF-VVCKTCGQQQT

0.01038

118 - 969

851

EEEGDCEEEEF-GVQIPCTCGKQ

0.0104

118 - 971

853

EEEGDCEEEEF-QIPCTCGKQAT

0.01039

118 - 1005

887

EEEGDCEEEEF-HGTFTCASEYT

0.01038

118 - 1015

897

EEEGDCEEEEF-TGNYQCGHYKH

0.0121

118 - 1029

911

EEEGDCEEEEF-KETLYCIDGAL

0.01047

118 - 1071

953

EEEGDCEEEEF-LDGVVCTEIDP

0.01038

118 - 1114

996

EEEGDCEEEEF-NFKFVCDNIKF

0.01046

118 - 1191

1073

EEEGDCEEEEF-KPNTWCIRCLW

0.01038

118 - 1194

1076

EEEGDCEEEEF-TWCIRCLWSTK

0.01037

118 - 1223

1105

EEEGDCEEEEF-MDNLACEDLKP

0.01082

118 - 1246

1128

EEEGDCEEEEF-KDVLECNVKTT

0.01037

118 - 1342

1224

EEEGDCEEEEF-NIVTRCLNRVC

0.01037

118 - 1347

1229

EEEGDCEEEEF-CLNRVCTNYMP

0.01037

118 - 1362

1244

EEEGDCEEEEF-LLLQLCTFTRS

0.01037

118 - 1392

1274

EEEGDCEEEEF-SVGKFCLEASF

0.01037

118 - 1421

1303

EEEGDCEEEEF-LLLSVCLGSLI

0.01037

118 - 1445

1327

EEEGDCEEEEF-GMPSYCTGYRE

0.01038

118 - 1464

1346

EEEGDCEEEEF-TIATYCTGSIP

0.01037

118 - 1470

1352

EEEGDCEEEEF-TGSIPCSVCLS

0.01068

118 - 1473

1355

EEEGDCEEEEF-IPCSVCLSGLD

0.01038

118 - 1586

1468

EEEGDCEEEEF-HVVDGCNSSTC

0.01037

118 - 1591

1473

EEEGDCEEEEF-CNSSTCMMCYK

0.01037

118 - 1594

1476

EEEGDCEEEEF-STCMMCYKRNR

0.01439

118 - 1605

1487

EEEGDCEEEEF-ATRVECTTIVN

0.01038

118 - 1627

1509

EEEGDCEEEEF-GGKGFCKLHNW

0.01145

118 - 1634

1516

EEEGDCEEEEF-LHNWNCVNCDT

0.01037

118 - 1637

1519

EEEGDCEEEEF-WNCVNCDTFCA

0.01059

118 - 1641

1523

EEEGDCEEEEF-NCDTFCAGSTF

0.01456

118 - 1731

1613

EEEGDCEEEEF-DGKSKCEESSA

0.01041

118 - 1748

1630

EEEGDCEEEEF-YSQLMCQPILL

0.0112

118 - 1836

1718

EEEGDCEEEEF-KDVVECLKLSH

0.01038

118 - 1852

1734

EEEGDCEEEEF-VTGDSCNNYML

0.01049

118 - 1873

1755

EEEGDCEEEEF-RDLGACIDCSA

0.01038

118 - 1876

1758

EEEGDCEEEEF-GACIDCSARHI

0.01037

118 - 1926

1808

EEEGDCEEEEF-PFKLTCATTRQ

0.01037

285 - 296

11

KVGGSCVLSGH-NLAKHCLHVVG

0.01078

285 - 347

62

KVGGSCVLSGH-HSLRVCVDTVR

0.01038

285 - 417

132

KVGGSCVLSGH-KKIKACVEEVT

0.01595

285 - 531

246

KVGGSCVLSGH-TVLKKCKSAFY

0.01097

285 - 574

289

KVGGSCVLSGH-KLMPVCVETKA

0.01062

285 - 856

571

KVGGSCVLSGH-WADNNCYLATA

0.01242

285 - 893

608

KVGGSCVLSGH-EAANFCALILA

0.01037

285 - 900

615

KVGGSCVLSGH-LILAYCNKTVG

0.01038

285 - 926

641

KVGGSCVLSGH-ANLDSCKRVLN

0.01066

285 - 934

649

KVGGSCVLSGH-VLNVVCKTCGQ

0.01068

285 - 937

652

KVGGSCVLSGH-VVCKTCGQQQT

0.01038

285 - 969

684

KVGGSCVLSGH-GVQIPCTCGKQ

0.01044

285 - 971

686

KVGGSCVLSGH-QIPCTCGKQAT

0.01098

285 - 1005

720

KVGGSCVLSGH-HGTFTCASEYT

0.01169

285 - 1015

730

KVGGSCVLSGH-TGNYQCGHYKH

0.01446

285 - 1029

744

KVGGSCVLSGH-KETLYCIDGAL

0.01069

285 - 1071

786

KVGGSCVLSGH-LDGVVCTEIDP

0.02752

285 - 1114

829

KVGGSCVLSGH-NFKFVCDNIKF

0.11443

285 - 1191

906

KVGGSCVLSGH-KPNTWCIRCLW

0.01104

285 - 1194

909

KVGGSCVLSGH-TWCIRCLWSTK

0.01037

285 - 1223

938

KVGGSCVLSGH-MDNLACEDLKP

0.01119

285 - 1246

961

KVGGSCVLSGH-KDVLECNVKTT

0.01057

285 - 1342

1057

KVGGSCVLSGH-NIVTRCLNRVC

0.01037

285 - 1347

1062

KVGGSCVLSGH-CLNRVCTNYMP

0.01037

285 - 1362

1077

KVGGSCVLSGH-LLLQLCTFTRS

0.01219

285 - 1392

1107

KVGGSCVLSGH-SVGKFCLEASF

0.01037

285 - 1421

1136

KVGGSCVLSGH-LLLSVCLGSLI

0.01041

285 - 1445

1160

KVGGSCVLSGH-GMPSYCTGYRE

0.01056

285 - 1464

1179

KVGGSCVLSGH-TIATYCTGSIP

0.01038

285 - 1470

1185

KVGGSCVLSGH-TGSIPCSVCLS

0.10547

285 - 1473

1188

KVGGSCVLSGH-IPCSVCLSGLD

0.01055

285 - 1586

1301

KVGGSCVLSGH-HVVDGCNSSTC

0.01044

285 - 1591

1306

KVGGSCVLSGH-CNSSTCMMCYK

0.01043

285 - 1594

1309

KVGGSCVLSGH-STCMMCYKRNR

0.01175

285 - 1605

1320

KVGGSCVLSGH-ATRVECTTIVN

0.0104

285 - 1627

1342

KVGGSCVLSGH-GGKGFCKLHNW

0.5664

285 - 1634

1349

KVGGSCVLSGH-LHNWNCVNCDT

0.0105

285 - 1637

1352

KVGGSCVLSGH-WNCVNCDTFCA

0.01066

285 - 1641

1356

KVGGSCVLSGH-NCDTFCAGSTF

0.13312

285 - 1731

1446

KVGGSCVLSGH-DGKSKCEESSA

0.01164

285 - 1748

1463

KVGGSCVLSGH-YSQLMCQPILL

0.26069

285 - 1836

1551

KVGGSCVLSGH-KDVVECLKLSH

0.01069

285 - 1852

1567

KVGGSCVLSGH-VTGDSCNNYML

0.01603

285 - 1873

1588

KVGGSCVLSGH-RDLGACIDCSA

0.01042

285 - 1876

1591

KVGGSCVLSGH-GACIDCSARHI

0.01106

285 - 1926

1641

KVGGSCVLSGH-PFKLTCATTRQ

0.01044

296 - 347

51

NLAKHCLHVVG-HSLRVCVDTVR

0.01455

296 - 417

121

NLAKHCLHVVG-KKIKACVEEVT

0.01057

296 - 531

235

NLAKHCLHVVG-TVLKKCKSAFY

0.01052

296 - 574

278

NLAKHCLHVVG-KLMPVCVETKA

0.0104

296 - 856

560

NLAKHCLHVVG-WADNNCYLATA

0.01039

296 - 893

597

NLAKHCLHVVG-EAANFCALILA

0.01049

296 - 900

604

NLAKHCLHVVG-LILAYCNKTVG

0.05653

296 - 926

630

NLAKHCLHVVG-ANLDSCKRVLN

0.01062

296 - 934

638

NLAKHCLHVVG-VLNVVCKTCGQ

0.01043

296 - 937

641

NLAKHCLHVVG-VVCKTCGQQQT

0.0829

296 - 969

673

NLAKHCLHVVG-GVQIPCTCGKQ

0.01039

296 - 971

675

NLAKHCLHVVG-QIPCTCGKQAT

0.0105

296 - 1005

709

NLAKHCLHVVG-HGTFTCASEYT

0.0106

296 - 1015

719

NLAKHCLHVVG-TGNYQCGHYKH

0.01059

296 - 1029

733

NLAKHCLHVVG-KETLYCIDGAL

0.01045

296 - 1071

775

NLAKHCLHVVG-LDGVVCTEIDP

0.01467

296 - 1114

818

NLAKHCLHVVG-NFKFVCDNIKF

0.01207

296 - 1191

895

NLAKHCLHVVG-KPNTWCIRCLW

0.01038

296 - 1194

898

NLAKHCLHVVG-TWCIRCLWSTK

0.01335

296 - 1223

927

NLAKHCLHVVG-MDNLACEDLKP

0.0105

296 - 1246

950

NLAKHCLHVVG-KDVLECNVKTT

0.02231

296 - 1342

1046

NLAKHCLHVVG-NIVTRCLNRVC

0.01042

296 - 1347

1051

NLAKHCLHVVG-CLNRVCTNYMP

0.01037

296 - 1362

1066

NLAKHCLHVVG-LLLQLCTFTRS

0.01039

296 - 1392

1096

NLAKHCLHVVG-SVGKFCLEASF

0.01037

296 - 1421

1125

NLAKHCLHVVG-LLLSVCLGSLI

0.01037

296 - 1445

1149

NLAKHCLHVVG-GMPSYCTGYRE

0.01039

296 - 1464

1168

NLAKHCLHVVG-TIATYCTGSIP

0.2882

296 - 1470

1174

NLAKHCLHVVG-TGSIPCSVCLS

0.01239

296 - 1473

1177

NLAKHCLHVVG-IPCSVCLSGLD

0.01309

296 - 1586

1290

NLAKHCLHVVG-HVVDGCNSSTC

0.01114

296 - 1591

1295

NLAKHCLHVVG-CNSSTCMMCYK

0.01038

296 - 1594

1298

NLAKHCLHVVG-STCMMCYKRNR

0.01426

296 - 1605

1309

NLAKHCLHVVG-ATRVECTTIVN

0.01037

296 - 1627

1331

NLAKHCLHVVG-GGKGFCKLHNW

0.01043

296 - 1634

1338

NLAKHCLHVVG-LHNWNCVNCDT

0.01084

296 - 1637

1341

NLAKHCLHVVG-WNCVNCDTFCA

0.01226

296 - 1641

1345

NLAKHCLHVVG-NCDTFCAGSTF

0.56374

296 - 1731

1435

NLAKHCLHVVG-DGKSKCEESSA

0.01075

296 - 1748

1452

NLAKHCLHVVG-YSQLMCQPILL

0.07916

296 - 1836

1540

NLAKHCLHVVG-KDVVECLKLSH

0.0104

296 - 1852

1556

NLAKHCLHVVG-VTGDSCNNYML

0.01081

296 - 1873

1577

NLAKHCLHVVG-RDLGACIDCSA

0.01037

296 - 1876

1580

NLAKHCLHVVG-GACIDCSARHI

0.03981

296 - 1926

1630

NLAKHCLHVVG-PFKLTCATTRQ

0.01038

347 - 417

70

HSLRVCVDTVR-KKIKACVEEVT

0.15833

347 - 531

184

HSLRVCVDTVR-TVLKKCKSAFY

0.07784

347 - 574

227

HSLRVCVDTVR-KLMPVCVETKA

0.012

347 - 856

509

HSLRVCVDTVR-WADNNCYLATA

0.0107

347 - 893

546

HSLRVCVDTVR-EAANFCALILA

0.0105

347 - 900

553

HSLRVCVDTVR-LILAYCNKTVG

0.01075

347 - 926

579

HSLRVCVDTVR-ANLDSCKRVLN

0.0107

347 - 934

587

HSLRVCVDTVR-VLNVVCKTCGQ

0.01082

347 - 937

590

HSLRVCVDTVR-VVCKTCGQQQT

0.01129

347 - 969

622

HSLRVCVDTVR-GVQIPCTCGKQ

0.01052

347 - 971

624

HSLRVCVDTVR-QIPCTCGKQAT

0.01442

347 - 1005

658

HSLRVCVDTVR-HGTFTCASEYT

0.015

347 - 1015

668

HSLRVCVDTVR-TGNYQCGHYKH

0.61951

347 - 1029

682

HSLRVCVDTVR-KETLYCIDGAL

0.01121

347 - 1071

724

HSLRVCVDTVR-LDGVVCTEIDP

0.01203

347 - 1114

767

HSLRVCVDTVR-NFKFVCDNIKF

0.03105

347 - 1191

844

HSLRVCVDTVR-KPNTWCIRCLW

0.01043

347 - 1194

847

HSLRVCVDTVR-TWCIRCLWSTK

0.01107

347 - 1223

876

HSLRVCVDTVR-MDNLACEDLKP

0.48796

347 - 1246

899

HSLRVCVDTVR-KDVLECNVKTT

0.01074

347 - 1342

995

HSLRVCVDTVR-NIVTRCLNRVC

0.0105

347 - 1347

1000

HSLRVCVDTVR-CLNRVCTNYMP

0.01933

347 - 1362

1015

HSLRVCVDTVR-LLLQLCTFTRS

0.01267

347 - 1392

1045

HSLRVCVDTVR-SVGKFCLEASF

0.01096

347 - 1421

1074

HSLRVCVDTVR-LLLSVCLGSLI

0.01045

347 - 1445

1098

HSLRVCVDTVR-GMPSYCTGYRE

0.01058

347 - 1464

1117

HSLRVCVDTVR-TIATYCTGSIP

0.01802

347 - 1470

1123

HSLRVCVDTVR-TGSIPCSVCLS

0.4005

347 - 1473

1126

HSLRVCVDTVR-IPCSVCLSGLD

0.02946

347 - 1586

1239

HSLRVCVDTVR-HVVDGCNSSTC

0.0105

347 - 1591

1244

HSLRVCVDTVR-CNSSTCMMCYK

0.01052

347 - 1594

1247

HSLRVCVDTVR-STCMMCYKRNR

0.01043

347 - 1605

1258

HSLRVCVDTVR-ATRVECTTIVN

0.03631

347 - 1627

1280

HSLRVCVDTVR-GGKGFCKLHNW

0.0104

347 - 1634

1287

HSLRVCVDTVR-LHNWNCVNCDT

0.01048

347 - 1637

1290

HSLRVCVDTVR-WNCVNCDTFCA

0.01239

347 - 1641

1294

HSLRVCVDTVR-NCDTFCAGSTF

0.99753

347 - 1731

1384

HSLRVCVDTVR-DGKSKCEESSA

0.01101

347 - 1748

1401

HSLRVCVDTVR-YSQLMCQPILL

0.99006

347 - 1836

1489

HSLRVCVDTVR-KDVVECLKLSH

0.01458

347 - 1852

1505

HSLRVCVDTVR-VTGDSCNNYML

0.97945

347 - 1873

1526

HSLRVCVDTVR-RDLGACIDCSA

0.01112

347 - 1876

1529

HSLRVCVDTVR-GACIDCSARHI

0.01107

347 - 1926

1579

HSLRVCVDTVR-PFKLTCATTRQ

0.0104

417 - 531

114

KKIKACVEEVT-TVLKKCKSAFY

0.01114

417 - 574

157

KKIKACVEEVT-KLMPVCVETKA

0.01049

417 - 856

439

KKIKACVEEVT-WADNNCYLATA

0.01162

417 - 893

476

KKIKACVEEVT-EAANFCALILA

0.0104

417 - 900

483

KKIKACVEEVT-LILAYCNKTVG

0.01066

417 - 926

509

KKIKACVEEVT-ANLDSCKRVLN

0.0104

417 - 934

517

KKIKACVEEVT-VLNVVCKTCGQ

0.01077

417 - 937

520

KKIKACVEEVT-VVCKTCGQQQT

0.01041

417 - 969

552

KKIKACVEEVT-GVQIPCTCGKQ

0.01045

417 - 971

554

KKIKACVEEVT-QIPCTCGKQAT

0.01146

417 - 1005

588

KKIKACVEEVT-HGTFTCASEYT

0.01993

417 - 1015

598

KKIKACVEEVT-TGNYQCGHYKH

0.20728

417 - 1029

612

KKIKACVEEVT-KETLYCIDGAL

0.01097

417 - 1071

654

KKIKACVEEVT-LDGVVCTEIDP

0.01302

417 - 1114

697

KKIKACVEEVT-NFKFVCDNIKF

0.02835

417 - 1191

774

KKIKACVEEVT-KPNTWCIRCLW

0.01074

417 - 1194

777

KKIKACVEEVT-TWCIRCLWSTK

0.01091

417 - 1223

806

KKIKACVEEVT-MDNLACEDLKP

0.9675

417 - 1246

829

KKIKACVEEVT-KDVLECNVKTT

0.01053

417 - 1342

925

KKIKACVEEVT-NIVTRCLNRVC

0.01054

417 - 1347

930

KKIKACVEEVT-CLNRVCTNYMP

0.01952

417 - 1362

945

KKIKACVEEVT-LLLQLCTFTRS

0.01827

417 - 1392

975

KKIKACVEEVT-SVGKFCLEASF

0.01097

417 - 1421

1004

KKIKACVEEVT-LLLSVCLGSLI

0.01047

417 - 1445

1028

KKIKACVEEVT-GMPSYCTGYRE

0.01054

417 - 1464

1047

KKIKACVEEVT-TIATYCTGSIP

0.01037

417 - 1470

1053

KKIKACVEEVT-TGSIPCSVCLS

0.19022

417 - 1473

1056

KKIKACVEEVT-IPCSVCLSGLD

0.04124

417 - 1586

1169

KKIKACVEEVT-HVVDGCNSSTC

0.01043

417 - 1591

1174

KKIKACVEEVT-CNSSTCMMCYK

0.01038

417 - 1594

1177

KKIKACVEEVT-STCMMCYKRNR

0.0304

417 - 1605

1188

KKIKACVEEVT-ATRVECTTIVN

0.23862

417 - 1627

1210

KKIKACVEEVT-GGKGFCKLHNW

0.12483

417 - 1634

1217

KKIKACVEEVT-LHNWNCVNCDT

0.01062

417 - 1637

1220

KKIKACVEEVT-WNCVNCDTFCA

0.01189

417 - 1641

1224

KKIKACVEEVT-NCDTFCAGSTF

0.28795

417 - 1731

1314

KKIKACVEEVT-DGKSKCEESSA

0.01113

417 - 1748

1331

KKIKACVEEVT-YSQLMCQPILL

0.01608

417 - 1836

1419

KKIKACVEEVT-KDVVECLKLSH

0.01089

417 - 1852

1435

KKIKACVEEVT-VTGDSCNNYML

0.07189

417 - 1873

1456

KKIKACVEEVT-RDLGACIDCSA

0.01226

417 - 1876

1459

KKIKACVEEVT-GACIDCSARHI

0.0104

417 - 1926

1509

KKIKACVEEVT-PFKLTCATTRQ

0.01039

531 - 574

43

TVLKKCKSAFY-KLMPVCVETKA

0.58597

531 - 856

325

TVLKKCKSAFY-WADNNCYLATA

0.01275

531 - 893

362

TVLKKCKSAFY-EAANFCALILA

0.01424

531 - 900

369

TVLKKCKSAFY-LILAYCNKTVG

0.01888

531 - 926

395

TVLKKCKSAFY-ANLDSCKRVLN

0.01274

531 - 934

403

TVLKKCKSAFY-VLNVVCKTCGQ

0.01407

531 - 937

406

TVLKKCKSAFY-VVCKTCGQQQT

0.01599

531 - 969

438

TVLKKCKSAFY-GVQIPCTCGKQ

0.01216

531 - 971

440

TVLKKCKSAFY-QIPCTCGKQAT

0.70904

531 - 1005

474

TVLKKCKSAFY-HGTFTCASEYT

0.16372

531 - 1015

484

TVLKKCKSAFY-TGNYQCGHYKH

0.95964

531 - 1029

498

TVLKKCKSAFY-KETLYCIDGAL

0.0295

531 - 1071

540

TVLKKCKSAFY-LDGVVCTEIDP

0.02929

531 - 1114

583

TVLKKCKSAFY-NFKFVCDNIKF

0.97039

531 - 1191

660

TVLKKCKSAFY-KPNTWCIRCLW

0.01129

531 - 1194

663

TVLKKCKSAFY-TWCIRCLWSTK

0.12207

531 - 1223

692

TVLKKCKSAFY-MDNLACEDLKP

0.99131

531 - 1246

715

TVLKKCKSAFY-KDVLECNVKTT

0.01414

531 - 1342

811

TVLKKCKSAFY-NIVTRCLNRVC

0.01176

531 - 1347

816

TVLKKCKSAFY-CLNRVCTNYMP

0.40761

531 - 1362

831

TVLKKCKSAFY-LLLQLCTFTRS

0.98164

531 - 1392

861

TVLKKCKSAFY-SVGKFCLEASF

0.01758

531 - 1421

890

TVLKKCKSAFY-LLLSVCLGSLI

0.01279

531 - 1445

914

TVLKKCKSAFY-GMPSYCTGYRE

0.02674

531 - 1464

933

TVLKKCKSAFY-TIATYCTGSIP

0.21097

531 - 1470

939

TVLKKCKSAFY-TGSIPCSVCLS

0.99799

531 - 1473

942

TVLKKCKSAFY-IPCSVCLSGLD

0.64854

531 - 1586

1055

TVLKKCKSAFY-HVVDGCNSSTC

0.01115

531 - 1591

1060

TVLKKCKSAFY-CNSSTCMMCYK

0.01147

531 - 1594

1063

TVLKKCKSAFY-STCMMCYKRNR

0.01311

531 - 1605

1074

TVLKKCKSAFY-ATRVECTTIVN

0.98477

531 - 1627

1096

TVLKKCKSAFY-GGKGFCKLHNW

0.01083

531 - 1634

1103

TVLKKCKSAFY-LHNWNCVNCDT

0.01505

531 - 1637

1106

TVLKKCKSAFY-WNCVNCDTFCA

0.10284

531 - 1641

1110

TVLKKCKSAFY-NCDTFCAGSTF

0.99939

531 - 1731

1200

TVLKKCKSAFY-DGKSKCEESSA

0.02224

531 - 1748

1217

TVLKKCKSAFY-YSQLMCQPILL

0.99934

531 - 1836

1305

TVLKKCKSAFY-KDVVECLKLSH

0.30987

531 - 1852

1321

TVLKKCKSAFY-VTGDSCNNYML

0.99967

531 - 1873

1342

TVLKKCKSAFY-RDLGACIDCSA

0.04013

531 - 1876

1345

TVLKKCKSAFY-GACIDCSARHI

0.01379

531 - 1926

1395

TVLKKCKSAFY-PFKLTCATTRQ

0.01047

574 - 856

282

KLMPVCVETKA-WADNNCYLATA

0.01037

574 - 893

319

KLMPVCVETKA-EAANFCALILA

0.01055

574 - 900

326

KLMPVCVETKA-LILAYCNKTVG

0.01116

574 - 926

352

KLMPVCVETKA-ANLDSCKRVLN

0.01039

574 - 934

360

KLMPVCVETKA-VLNVVCKTCGQ

0.01084

574 - 937

363

KLMPVCVETKA-VVCKTCGQQQT

0.03323

574 - 969

395

KLMPVCVETKA-GVQIPCTCGKQ

0.01037

574 - 971

397

KLMPVCVETKA-QIPCTCGKQAT

0.01039

574 - 1005

431

KLMPVCVETKA-HGTFTCASEYT

0.01051

574 - 1015

441

KLMPVCVETKA-TGNYQCGHYKH

0.01063

574 - 1029

455

KLMPVCVETKA-KETLYCIDGAL

0.01045

574 - 1071

497

KLMPVCVETKA-LDGVVCTEIDP

0.01186

574 - 1114

540

KLMPVCVETKA-NFKFVCDNIKF

0.0161

574 - 1191

617

KLMPVCVETKA-KPNTWCIRCLW

0.01037

574 - 1194

620

KLMPVCVETKA-TWCIRCLWSTK

0.01039

574 - 1223

649

KLMPVCVETKA-MDNLACEDLKP

0.01699

574 - 1246

672

KLMPVCVETKA-KDVLECNVKTT

0.01319

574 - 1342

768

KLMPVCVETKA-NIVTRCLNRVC

0.01039

574 - 1347

773

KLMPVCVETKA-CLNRVCTNYMP

0.01044

574 - 1362

788

KLMPVCVETKA-LLLQLCTFTRS

0.01049

574 - 1392

818

KLMPVCVETKA-SVGKFCLEASF

0.01037

574 - 1421

847

KLMPVCVETKA-LLLSVCLGSLI

0.01037

574 - 1445

871

KLMPVCVETKA-GMPSYCTGYRE

0.01038

574 - 1464

890

KLMPVCVETKA-TIATYCTGSIP

0.01292

574 - 1470

896

KLMPVCVETKA-TGSIPCSVCLS

0.01322

574 - 1473

899

KLMPVCVETKA-IPCSVCLSGLD

0.01115

574 - 1586

1012

KLMPVCVETKA-HVVDGCNSSTC

0.01057

574 - 1591

1017

KLMPVCVETKA-CNSSTCMMCYK

0.01037

574 - 1594

1020

KLMPVCVETKA-STCMMCYKRNR

0.01039

574 - 1605

1031

KLMPVCVETKA-ATRVECTTIVN

0.01039

574 - 1627

1053

KLMPVCVETKA-GGKGFCKLHNW

0.01038

574 - 1634

1060

KLMPVCVETKA-LHNWNCVNCDT

0.01039

574 - 1637

1063

KLMPVCVETKA-WNCVNCDTFCA

0.01137

574 - 1641

1067

KLMPVCVETKA-NCDTFCAGSTF

0.02021

574 - 1731

1157

KLMPVCVETKA-DGKSKCEESSA

0.01044

574 - 1748

1174

KLMPVCVETKA-YSQLMCQPILL

0.01385

574 - 1836

1262

KLMPVCVETKA-KDVVECLKLSH

0.01044

574 - 1852

1278

KLMPVCVETKA-VTGDSCNNYML

0.02149

574 - 1873

1299

KLMPVCVETKA-RDLGACIDCSA

0.01038

574 - 1876

1302

KLMPVCVETKA-GACIDCSARHI

0.01197

574 - 1926

1352

KLMPVCVETKA-PFKLTCATTRQ

0.0104

856 - 893

37

WADNNCYLATA-EAANFCALILA

0.01042

856 - 900

44

WADNNCYLATA-LILAYCNKTVG

0.0106

856 - 926

70

WADNNCYLATA-ANLDSCKRVLN

0.01037

856 - 934

78

WADNNCYLATA-VLNVVCKTCGQ

0.01037

856 - 937

81

WADNNCYLATA-VVCKTCGQQQT

0.02246

856 - 969

113

WADNNCYLATA-GVQIPCTCGKQ

0.01037

856 - 971

115

WADNNCYLATA-QIPCTCGKQAT

0.01037

856 - 1005

149

WADNNCYLATA-HGTFTCASEYT

0.01037

856 - 1015

159

WADNNCYLATA-TGNYQCGHYKH

0.01037

856 - 1029

173

WADNNCYLATA-KETLYCIDGAL

0.01038

856 - 1071

215

WADNNCYLATA-LDGVVCTEIDP

0.0104

856 - 1114

258

WADNNCYLATA-NFKFVCDNIKF

0.01061

856 - 1191

335

WADNNCYLATA-KPNTWCIRCLW

0.01037

856 - 1194

338

WADNNCYLATA-TWCIRCLWSTK

0.01038

856 - 1223

367

WADNNCYLATA-MDNLACEDLKP

0.01039

856 - 1246

390

WADNNCYLATA-KDVLECNVKTT

0.01045

856 - 1342

486

WADNNCYLATA-NIVTRCLNRVC

0.01038

856 - 1347

491

WADNNCYLATA-CLNRVCTNYMP

0.01037

856 - 1362

506

WADNNCYLATA-LLLQLCTFTRS

0.01045

856 - 1392

536

WADNNCYLATA-SVGKFCLEASF

0.01037

856 - 1421

565

WADNNCYLATA-LLLSVCLGSLI

0.01037

856 - 1445

589

WADNNCYLATA-GMPSYCTGYRE

0.01037

856 - 1464

608

WADNNCYLATA-TIATYCTGSIP

0.01415

856 - 1470

614

WADNNCYLATA-TGSIPCSVCLS

0.01049

856 - 1473

617

WADNNCYLATA-IPCSVCLSGLD

0.01047

856 - 1586

730

WADNNCYLATA-HVVDGCNSSTC

0.0104

856 - 1591

735

WADNNCYLATA-CNSSTCMMCYK

0.01037

856 - 1594

738

WADNNCYLATA-STCMMCYKRNR

0.01037

856 - 1605

749

WADNNCYLATA-ATRVECTTIVN

0.01037

856 - 1627

771

WADNNCYLATA-GGKGFCKLHNW

0.0104

856 - 1634

778

WADNNCYLATA-LHNWNCVNCDT

0.01037

856 - 1637

781

WADNNCYLATA-WNCVNCDTFCA

0.01097

856 - 1641

785

WADNNCYLATA-NCDTFCAGSTF

0.97618

856 - 1731

875

WADNNCYLATA-DGKSKCEESSA

0.01037

856 - 1748

892

WADNNCYLATA-YSQLMCQPILL

0.01134

856 - 1836

980

WADNNCYLATA-KDVVECLKLSH

0.01037

856 - 1852

996

WADNNCYLATA-VTGDSCNNYML

0.0106

856 - 1873

1017

WADNNCYLATA-RDLGACIDCSA

0.01037

856 - 1876

1020

WADNNCYLATA-GACIDCSARHI

0.011

856 - 1926

1070

WADNNCYLATA-PFKLTCATTRQ

0.01037

893 - 900

7

EAANFCALILA-LILAYCNKTVG

0.01043

893 - 926

33

EAANFCALILA-ANLDSCKRVLN

0.01068

893 - 934

41

EAANFCALILA-VLNVVCKTCGQ

0.01127

893 - 937

44

EAANFCALILA-VVCKTCGQQQT

0.01058

893 - 969

76

EAANFCALILA-GVQIPCTCGKQ

0.01041

893 - 971

78

EAANFCALILA-QIPCTCGKQAT

0.01062

893 - 1005

112

EAANFCALILA-HGTFTCASEYT

0.01789

893 - 1015

122

EAANFCALILA-TGNYQCGHYKH

0.04748

893 - 1029

136

EAANFCALILA-KETLYCIDGAL

0.01063

893 - 1071

178

EAANFCALILA-LDGVVCTEIDP

0.01781

893 - 1114

221

EAANFCALILA-NFKFVCDNIKF

0.23477

893 - 1191

298

EAANFCALILA-KPNTWCIRCLW

0.01075

893 - 1194

301

EAANFCALILA-TWCIRCLWSTK

0.0104

893 - 1223

330

EAANFCALILA-MDNLACEDLKP

0.01141

893 - 1246

353

EAANFCALILA-KDVLECNVKTT

0.01048

893 - 1342

449

EAANFCALILA-NIVTRCLNRVC

0.01037

893 - 1347

454

EAANFCALILA-CLNRVCTNYMP

0.01066

893 - 1362

469

EAANFCALILA-LLLQLCTFTRS

0.01043

893 - 1392

499

EAANFCALILA-SVGKFCLEASF

0.01038

893 - 1421

528

EAANFCALILA-LLLSVCLGSLI

0.01037

893 - 1445

552

EAANFCALILA-GMPSYCTGYRE

0.0105

893 - 1464

571

EAANFCALILA-TIATYCTGSIP

0.0105

893 - 1470

577

EAANFCALILA-TGSIPCSVCLS

0.11883

893 - 1473

580

EAANFCALILA-IPCSVCLSGLD

0.01133

893 - 1586

693

EAANFCALILA-HVVDGCNSSTC

0.01044

893 - 1591

698

EAANFCALILA-CNSSTCMMCYK

0.01039

893 - 1594

701

EAANFCALILA-STCMMCYKRNR

0.0117

893 - 1605

712

EAANFCALILA-ATRVECTTIVN

0.01048

893 - 1627

734

EAANFCALILA-GGKGFCKLHNW

0.20434

893 - 1634

741

EAANFCALILA-LHNWNCVNCDT

0.01209

893 - 1637

744

EAANFCALILA-WNCVNCDTFCA

0.01346

893 - 1641

748

EAANFCALILA-NCDTFCAGSTF

0.39424

893 - 1731

838

EAANFCALILA-DGKSKCEESSA

0.01086

893 - 1748

855

EAANFCALILA-YSQLMCQPILL

0.01615

893 - 1836

943

EAANFCALILA-KDVVECLKLSH

0.01039

893 - 1852

959

EAANFCALILA-VTGDSCNNYML

0.76236

893 - 1873

980

EAANFCALILA-RDLGACIDCSA

0.01039

893 - 1876

983

EAANFCALILA-GACIDCSARHI

0.01043

893 - 1926

1033

EAANFCALILA-PFKLTCATTRQ

0.01039

900 - 926

26

LILAYCNKTVG-ANLDSCKRVLN

0.01044

900 - 934

34

LILAYCNKTVG-VLNVVCKTCGQ

0.0137

900 - 937

37

LILAYCNKTVG-VVCKTCGQQQT

0.01086

900 - 969

69

LILAYCNKTVG-GVQIPCTCGKQ

0.01048

900 - 971

71

LILAYCNKTVG-QIPCTCGKQAT

0.06193

900 - 1005

105

LILAYCNKTVG-HGTFTCASEYT

0.22033

900 - 1015

115

LILAYCNKTVG-TGNYQCGHYKH

0.03711

900 - 1029

129

LILAYCNKTVG-KETLYCIDGAL

0.01091

900 - 1071

171

LILAYCNKTVG-LDGVVCTEIDP

0.08216

900 - 1114

214

LILAYCNKTVG-NFKFVCDNIKF

0.96887

900 - 1191

291

LILAYCNKTVG-KPNTWCIRCLW

0.01217

900 - 1194

294

LILAYCNKTVG-TWCIRCLWSTK

0.01358

900 - 1223

323

LILAYCNKTVG-MDNLACEDLKP

0.99663

900 - 1246

346

LILAYCNKTVG-KDVLECNVKTT

0.01116

900 - 1342

442

LILAYCNKTVG-NIVTRCLNRVC

0.01088

900 - 1347

447

LILAYCNKTVG-CLNRVCTNYMP

0.98893

900 - 1362

462

LILAYCNKTVG-LLLQLCTFTRS

0.99448

900 - 1392

492

LILAYCNKTVG-SVGKFCLEASF

0.03342

900 - 1421

521

LILAYCNKTVG-LLLSVCLGSLI

0.01239

900 - 1445

545

LILAYCNKTVG-GMPSYCTGYRE

0.01094

900 - 1464

564

LILAYCNKTVG-TIATYCTGSIP

0.01138

900 - 1470

570

LILAYCNKTVG-TGSIPCSVCLS

0.76296

900 - 1473

573

LILAYCNKTVG-IPCSVCLSGLD

0.01548

900 - 1586

686

LILAYCNKTVG-HVVDGCNSSTC

0.01072

900 - 1591

691

LILAYCNKTVG-CNSSTCMMCYK

0.01046

900 - 1594

694

LILAYCNKTVG-STCMMCYKRNR

0.01065

900 - 1605

705

LILAYCNKTVG-ATRVECTTIVN

0.80037

900 - 1627

727

LILAYCNKTVG-GGKGFCKLHNW

0.01147

900 - 1634

734

LILAYCNKTVG-LHNWNCVNCDT

0.02149

900 - 1637

737

LILAYCNKTVG-WNCVNCDTFCA

0.01127

900 - 1641

741

LILAYCNKTVG-NCDTFCAGSTF

0.05783

900 - 1731

831

LILAYCNKTVG-DGKSKCEESSA

0.03303

900 - 1748

848

LILAYCNKTVG-YSQLMCQPILL

0.36466

900 - 1836

936

LILAYCNKTVG-KDVVECLKLSH

0.01354

900 - 1852

952

LILAYCNKTVG-VTGDSCNNYML

0.15745

900 - 1873

973

LILAYCNKTVG-RDLGACIDCSA

0.88205

900 - 1876

976

LILAYCNKTVG-GACIDCSARHI

0.01055

900 - 1926

1026

LILAYCNKTVG-PFKLTCATTRQ

0.01093

926 - 934

8

ANLDSCKRVLN-VLNVVCKTCGQ

0.01037

926 - 937

11

ANLDSCKRVLN-VVCKTCGQQQT

0.99821

926 - 969

43

ANLDSCKRVLN-GVQIPCTCGKQ

0.01064

926 - 971

45

ANLDSCKRVLN-QIPCTCGKQAT

0.01042

926 - 1005

79

ANLDSCKRVLN-HGTFTCASEYT

0.01272

926 - 1015

89

ANLDSCKRVLN-TGNYQCGHYKH

0.02159

926 - 1029

103

ANLDSCKRVLN-KETLYCIDGAL

0.01897

926 - 1071

145

ANLDSCKRVLN-LDGVVCTEIDP

0.01041

926 - 1114

188

ANLDSCKRVLN-NFKFVCDNIKF

0.0104

926 - 1191

265

ANLDSCKRVLN-KPNTWCIRCLW

0.01131

926 - 1194

268

ANLDSCKRVLN-TWCIRCLWSTK

0.99882

926 - 1223

297

ANLDSCKRVLN-MDNLACEDLKP

0.07596

926 - 1246

320

ANLDSCKRVLN-KDVLECNVKTT

0.99796

926 - 1342

416

ANLDSCKRVLN-NIVTRCLNRVC

0.01114

926 - 1347

421

ANLDSCKRVLN-CLNRVCTNYMP

0.0104

926 - 1362

436

ANLDSCKRVLN-LLLQLCTFTRS

0.01266

926 - 1392

466

ANLDSCKRVLN-SVGKFCLEASF

0.01052

926 - 1421

495

ANLDSCKRVLN-LLLSVCLGSLI

0.01041

926 - 1445

519

ANLDSCKRVLN-GMPSYCTGYRE

0.01042

926 - 1464

538

ANLDSCKRVLN-TIATYCTGSIP

0.99956

926 - 1470

544

ANLDSCKRVLN-TGSIPCSVCLS

0.01037

926 - 1473

547

ANLDSCKRVLN-IPCSVCLSGLD

0.03663

926 - 1586

660

ANLDSCKRVLN-HVVDGCNSSTC

0.67392

926 - 1591

665

ANLDSCKRVLN-CNSSTCMMCYK

0.01037

926 - 1594

668

ANLDSCKRVLN-STCMMCYKRNR

0.69395

926 - 1605

679

ANLDSCKRVLN-ATRVECTTIVN

0.01235

926 - 1627

701

ANLDSCKRVLN-GGKGFCKLHNW

0.04492

926 - 1634

708

ANLDSCKRVLN-LHNWNCVNCDT

0.99803

926 - 1637

711

ANLDSCKRVLN-WNCVNCDTFCA

0.97965

926 - 1641

715

ANLDSCKRVLN-NCDTFCAGSTF

0.01131

926 - 1731

805

ANLDSCKRVLN-DGKSKCEESSA

0.01037

926 - 1748

822

ANLDSCKRVLN-YSQLMCQPILL

0.01037

926 - 1836

910

ANLDSCKRVLN-KDVVECLKLSH

0.01042

926 - 1852

926

ANLDSCKRVLN-VTGDSCNNYML

0.01083

926 - 1873

947

ANLDSCKRVLN-RDLGACIDCSA

0.01246

926 - 1876

950

ANLDSCKRVLN-GACIDCSARHI

0.998

926 - 1926

1000

ANLDSCKRVLN-PFKLTCATTRQ

0.01091

934 - 937

3

VLNVVCKTCGQ-VVCKTCGQQQT

0.0114

934 - 969

35

VLNVVCKTCGQ-GVQIPCTCGKQ

0.07884

934 - 971

37

VLNVVCKTCGQ-QIPCTCGKQAT

0.01042

934 - 1005

71

VLNVVCKTCGQ-HGTFTCASEYT

0.16653

934 - 1015

81

VLNVVCKTCGQ-TGNYQCGHYKH

0.98999

934 - 1029

95

VLNVVCKTCGQ-KETLYCIDGAL

0.01091

934 - 1071

137

VLNVVCKTCGQ-LDGVVCTEIDP

0.99811

934 - 1114

180

VLNVVCKTCGQ-NFKFVCDNIKF

0.01347

934 - 1191

257

VLNVVCKTCGQ-KPNTWCIRCLW

0.05673

934 - 1194

260

VLNVVCKTCGQ-TWCIRCLWSTK

0.01123

934 - 1223

289

VLNVVCKTCGQ-MDNLACEDLKP

0.99771

934 - 1246

312

VLNVVCKTCGQ-KDVLECNVKTT

0.01696

934 - 1342

408

VLNVVCKTCGQ-NIVTRCLNRVC

0.01064

934 - 1347

413

VLNVVCKTCGQ-CLNRVCTNYMP

0.38734

934 - 1362

428

VLNVVCKTCGQ-LLLQLCTFTRS

0.99335

934 - 1392

458

VLNVVCKTCGQ-SVGKFCLEASF

0.01105

934 - 1421

487

VLNVVCKTCGQ-LLLSVCLGSLI

0.0108

934 - 1445

511

VLNVVCKTCGQ-GMPSYCTGYRE

0.3438

934 - 1464

530

VLNVVCKTCGQ-TIATYCTGSIP

0.02894

934 - 1470

536

VLNVVCKTCGQ-TGSIPCSVCLS

0.01143

934 - 1473

539

VLNVVCKTCGQ-IPCSVCLSGLD

0.01496

934 - 1586

652

VLNVVCKTCGQ-HVVDGCNSSTC

0.01038

934 - 1591

657

VLNVVCKTCGQ-CNSSTCMMCYK

0.0104

934 - 1594

660

VLNVVCKTCGQ-STCMMCYKRNR

0.8515

934 - 1605

671

VLNVVCKTCGQ-ATRVECTTIVN

0.99544

934 - 1627

693

VLNVVCKTCGQ-GGKGFCKLHNW

0.99733

934 - 1634

700

VLNVVCKTCGQ-LHNWNCVNCDT

0.30542

934 - 1637

703

VLNVVCKTCGQ-WNCVNCDTFCA

0.03455

934 - 1641

707

VLNVVCKTCGQ-NCDTFCAGSTF

0.99845

934 - 1731

797

VLNVVCKTCGQ-DGKSKCEESSA

0.03308

934 - 1748

814

VLNVVCKTCGQ-YSQLMCQPILL

0.01188

934 - 1836

902

VLNVVCKTCGQ-KDVVECLKLSH

0.01072

934 - 1852

918

VLNVVCKTCGQ-VTGDSCNNYML

0.99536

934 - 1873

939

VLNVVCKTCGQ-RDLGACIDCSA

0.96893

934 - 1876

942

VLNVVCKTCGQ-GACIDCSARHI

0.0414

934 - 1926

992

VLNVVCKTCGQ-PFKLTCATTRQ

0.01103

937 - 969

32

VVCKTCGQQQT-GVQIPCTCGKQ

0.01042

937 - 971

34

VVCKTCGQQQT-QIPCTCGKQAT

0.01182

937 - 1005

68

VVCKTCGQQQT-HGTFTCASEYT

0.0109

937 - 1015

78

VVCKTCGQQQT-TGNYQCGHYKH

0.01235

937 - 1029

92

VVCKTCGQQQT-KETLYCIDGAL

0.01172

937 - 1071

134

VVCKTCGQQQT-LDGVVCTEIDP

0.01052

937 - 1114

177

VVCKTCGQQQT-NFKFVCDNIKF

0.01551

937 - 1191

254

VVCKTCGQQQT-KPNTWCIRCLW

0.01041

937 - 1194

257

VVCKTCGQQQT-TWCIRCLWSTK

0.01042

937 - 1223

286

VVCKTCGQQQT-MDNLACEDLKP

0.01047

937 - 1246

309

VVCKTCGQQQT-KDVLECNVKTT

0.01062

937 - 1342

405

VVCKTCGQQQT-NIVTRCLNRVC

0.01037

937 - 1347

410

VVCKTCGQQQT-CLNRVCTNYMP

0.01037

937 - 1362

425

VVCKTCGQQQT-LLLQLCTFTRS

0.01044

937 - 1392

455

VVCKTCGQQQT-SVGKFCLEASF

0.01037

937 - 1421

484

VVCKTCGQQQT-LLLSVCLGSLI

0.01038

937 - 1445

508

VVCKTCGQQQT-GMPSYCTGYRE

0.01043

937 - 1464

527

VVCKTCGQQQT-TIATYCTGSIP

0.01823

937 - 1470

533

VVCKTCGQQQT-TGSIPCSVCLS

0.02492

937 - 1473

536

VVCKTCGQQQT-IPCSVCLSGLD

0.01061

937 - 1586

649

VVCKTCGQQQT-HVVDGCNSSTC

0.01056

937 - 1591

654

VVCKTCGQQQT-CNSSTCMMCYK

0.01039

937 - 1594

657

VVCKTCGQQQT-STCMMCYKRNR

0.01042

937 - 1605

668

VVCKTCGQQQT-ATRVECTTIVN

0.01037

937 - 1627

690

VVCKTCGQQQT-GGKGFCKLHNW

0.02857

937 - 1634

697

VVCKTCGQQQT-LHNWNCVNCDT

0.01045

937 - 1637

700

VVCKTCGQQQT-WNCVNCDTFCA

0.01085

937 - 1641

704

VVCKTCGQQQT-NCDTFCAGSTF

0.99993

937 - 1731

794

VVCKTCGQQQT-DGKSKCEESSA

0.01042

937 - 1748

811

VVCKTCGQQQT-YSQLMCQPILL

0.03076

937 - 1836

899

VVCKTCGQQQT-KDVVECLKLSH

0.01078

937 - 1852

915

VVCKTCGQQQT-VTGDSCNNYML

0.0378

937 - 1873

936

VVCKTCGQQQT-RDLGACIDCSA

0.01037

937 - 1876

939

VVCKTCGQQQT-GACIDCSARHI

0.01046

937 - 1926

989

VVCKTCGQQQT-PFKLTCATTRQ

0.01046

969 - 971

2

GVQIPCTCGKQ-QIPCTCGKQAT

0.01038

969 - 1005

36

GVQIPCTCGKQ-HGTFTCASEYT

0.01037

969 - 1015

46

GVQIPCTCGKQ-TGNYQCGHYKH

0.07692

969 - 1029

60

GVQIPCTCGKQ-KETLYCIDGAL

0.01037

969 - 1071

102

GVQIPCTCGKQ-LDGVVCTEIDP

0.01038

969 - 1114

145

GVQIPCTCGKQ-NFKFVCDNIKF

0.01037

969 - 1191

222

GVQIPCTCGKQ-KPNTWCIRCLW

0.01041

969 - 1194

225

GVQIPCTCGKQ-TWCIRCLWSTK

0.0104

969 - 1223

254

GVQIPCTCGKQ-MDNLACEDLKP

0.01043

969 - 1246

277

GVQIPCTCGKQ-KDVLECNVKTT

0.01037

969 - 1342

373

GVQIPCTCGKQ-NIVTRCLNRVC

0.01039

969 - 1347

378

GVQIPCTCGKQ-CLNRVCTNYMP

0.01037

969 - 1362

393

GVQIPCTCGKQ-LLLQLCTFTRS

0.01125

969 - 1392

423

GVQIPCTCGKQ-SVGKFCLEASF

0.01159

969 - 1421

452

GVQIPCTCGKQ-LLLSVCLGSLI

0.78375

969 - 1445

476

GVQIPCTCGKQ-GMPSYCTGYRE

0.01117

969 - 1464

495

GVQIPCTCGKQ-TIATYCTGSIP

0.0104

969 - 1470

501

GVQIPCTCGKQ-TGSIPCSVCLS

0.01041

969 - 1473

504

GVQIPCTCGKQ-IPCSVCLSGLD

0.01037

969 - 1586

617

GVQIPCTCGKQ-HVVDGCNSSTC

0.01037

969 - 1591

622

GVQIPCTCGKQ-CNSSTCMMCYK

0.01064

969 - 1594

625

GVQIPCTCGKQ-STCMMCYKRNR

0.01599

969 - 1605

636

GVQIPCTCGKQ-ATRVECTTIVN

0.01037

969 - 1627

658

GVQIPCTCGKQ-GGKGFCKLHNW

0.50443

969 - 1634

665

GVQIPCTCGKQ-LHNWNCVNCDT

0.01037

969 - 1637

668

GVQIPCTCGKQ-WNCVNCDTFCA

0.0104

969 - 1641

672

GVQIPCTCGKQ-NCDTFCAGSTF

0.72664

969 - 1731

762

GVQIPCTCGKQ-DGKSKCEESSA

0.01039

969 - 1748

779

GVQIPCTCGKQ-YSQLMCQPILL

0.01043

969 - 1836

867

GVQIPCTCGKQ-KDVVECLKLSH

0.01037

969 - 1852

883

GVQIPCTCGKQ-VTGDSCNNYML

0.01039

969 - 1873

904

GVQIPCTCGKQ-RDLGACIDCSA

0.03494

969 - 1876

907

GVQIPCTCGKQ-GACIDCSARHI

0.01044

969 - 1926

957

GVQIPCTCGKQ-PFKLTCATTRQ

0.01037

971 - 1005

34

QIPCTCGKQAT-HGTFTCASEYT

0.01044

971 - 1015

44

QIPCTCGKQAT-TGNYQCGHYKH

0.01042

971 - 1029

58

QIPCTCGKQAT-KETLYCIDGAL

0.01038

971 - 1071

100

QIPCTCGKQAT-LDGVVCTEIDP

0.01041

971 - 1114

143

QIPCTCGKQAT-NFKFVCDNIKF

0.01044

971 - 1191

220

QIPCTCGKQAT-KPNTWCIRCLW

0.01037

971 - 1194

223

QIPCTCGKQAT-TWCIRCLWSTK

0.0104

971 - 1223

252

QIPCTCGKQAT-MDNLACEDLKP

0.01483

971 - 1246

275

QIPCTCGKQAT-KDVLECNVKTT

0.0104

971 - 1342

371

QIPCTCGKQAT-NIVTRCLNRVC

0.01037

971 - 1347

376

QIPCTCGKQAT-CLNRVCTNYMP

0.01043

971 - 1362

391

QIPCTCGKQAT-LLLQLCTFTRS

0.01063

971 - 1392

421

QIPCTCGKQAT-SVGKFCLEASF

0.01037

971 - 1421

450

QIPCTCGKQAT-LLLSVCLGSLI

0.01047

971 - 1445

474

QIPCTCGKQAT-GMPSYCTGYRE

0.01037

971 - 1464

493

QIPCTCGKQAT-TIATYCTGSIP

0.01126

971 - 1470

499

QIPCTCGKQAT-TGSIPCSVCLS

0.0119

971 - 1473

502

QIPCTCGKQAT-IPCSVCLSGLD

0.01058

971 - 1586

615

QIPCTCGKQAT-HVVDGCNSSTC

0.01038

971 - 1591

620

QIPCTCGKQAT-CNSSTCMMCYK

0.01037

971 - 1594

623

QIPCTCGKQAT-STCMMCYKRNR

0.01041

971 - 1605

634

QIPCTCGKQAT-ATRVECTTIVN

0.0106

971 - 1627

656

QIPCTCGKQAT-GGKGFCKLHNW

0.01049

971 - 1634

663

QIPCTCGKQAT-LHNWNCVNCDT

0.01038

971 - 1637

666

QIPCTCGKQAT-WNCVNCDTFCA

0.01051

971 - 1641

670

QIPCTCGKQAT-NCDTFCAGSTF

0.02113

971 - 1731

760

QIPCTCGKQAT-DGKSKCEESSA

0.01037

971 - 1748

777

QIPCTCGKQAT-YSQLMCQPILL

0.0104

971 - 1836

865

QIPCTCGKQAT-KDVVECLKLSH

0.01037

971 - 1852

881

QIPCTCGKQAT-VTGDSCNNYML

0.01069

971 - 1873

902

QIPCTCGKQAT-RDLGACIDCSA

0.01111

971 - 1876

905

QIPCTCGKQAT-GACIDCSARHI

0.01044

971 - 1926

955

QIPCTCGKQAT-PFKLTCATTRQ

0.01037

1005 - 1015

10

HGTFTCASEYT-TGNYQCGHYKH

0.97507

1005 - 1029

24

HGTFTCASEYT-KETLYCIDGAL

0.01038

1005 - 1071

66

HGTFTCASEYT-LDGVVCTEIDP

0.96444

1005 - 1114

109

HGTFTCASEYT-NFKFVCDNIKF

0.01106

1005 - 1191

186

HGTFTCASEYT-KPNTWCIRCLW

0.32284

1005 - 1194

189

HGTFTCASEYT-TWCIRCLWSTK

0.01042

1005 - 1223

218

HGTFTCASEYT-MDNLACEDLKP

0.01037

1005 - 1246

241

HGTFTCASEYT-KDVLECNVKTT

0.01054

1005 - 1342

337

HGTFTCASEYT-NIVTRCLNRVC

0.01038

1005 - 1347

342

HGTFTCASEYT-CLNRVCTNYMP

0.0104

1005 - 1362

357

HGTFTCASEYT-LLLQLCTFTRS

0.01045

1005 - 1392

387

HGTFTCASEYT-SVGKFCLEASF

0.0104

1005 - 1421

416

HGTFTCASEYT-LLLSVCLGSLI

0.01037

1005 - 1445

440

HGTFTCASEYT-GMPSYCTGYRE

0.01698

1005 - 1464

459

HGTFTCASEYT-TIATYCTGSIP

0.01098

1005 - 1470

465

HGTFTCASEYT-TGSIPCSVCLS

0.01055

1005 - 1473

468

HGTFTCASEYT-IPCSVCLSGLD

0.01038

1005 - 1586

581

HGTFTCASEYT-HVVDGCNSSTC

0.01039

1005 - 1591

586

HGTFTCASEYT-CNSSTCMMCYK

0.01051

1005 - 1594

589

HGTFTCASEYT-STCMMCYKRNR

0.03833

1005 - 1605

600

HGTFTCASEYT-ATRVECTTIVN

0.01101

1005 - 1627

622

HGTFTCASEYT-GGKGFCKLHNW

0.99284

1005 - 1634

629

HGTFTCASEYT-LHNWNCVNCDT

0.01074

1005 - 1637

632

HGTFTCASEYT-WNCVNCDTFCA

0.01054

1005 - 1641

636

HGTFTCASEYT-NCDTFCAGSTF

0.01693

1005 - 1731

726

HGTFTCASEYT-DGKSKCEESSA

0.02559

1005 - 1748

743

HGTFTCASEYT-YSQLMCQPILL

0.01122

1005 - 1836

831

HGTFTCASEYT-KDVVECLKLSH

0.01038

1005 - 1852

847

HGTFTCASEYT-VTGDSCNNYML

0.04967

1005 - 1873

868

HGTFTCASEYT-RDLGACIDCSA

0.01037

1005 - 1876

871

HGTFTCASEYT-GACIDCSARHI

0.79428

1005 - 1926

921

HGTFTCASEYT-PFKLTCATTRQ

0.01038

1015 - 1029

14

TGNYQCGHYKH-KETLYCIDGAL

0.02216

1015 - 1071

56

TGNYQCGHYKH-LDGVVCTEIDP

0.0105

1015 - 1114

99

TGNYQCGHYKH-NFKFVCDNIKF

0.01041

1015 - 1191

176

TGNYQCGHYKH-KPNTWCIRCLW

0.0104

1015 - 1194

179

TGNYQCGHYKH-TWCIRCLWSTK

0.10065

1015 - 1223

208

TGNYQCGHYKH-MDNLACEDLKP

0.40779

1015 - 1246

231

TGNYQCGHYKH-KDVLECNVKTT

0.99756

1015 - 1342

327

TGNYQCGHYKH-NIVTRCLNRVC

0.01277

1015 - 1347

332

TGNYQCGHYKH-CLNRVCTNYMP

0.01043

1015 - 1362

347

TGNYQCGHYKH-LLLQLCTFTRS

0.01088

1015 - 1392

377

TGNYQCGHYKH-SVGKFCLEASF

0.01066

1015 - 1421

406

TGNYQCGHYKH-LLLSVCLGSLI

0.01083

1015 - 1445

430

TGNYQCGHYKH-GMPSYCTGYRE

0.01056

1015 - 1464

449

TGNYQCGHYKH-TIATYCTGSIP

0.99962

1015 - 1470

455

TGNYQCGHYKH-TGSIPCSVCLS

0.01044

1015 - 1473

458

TGNYQCGHYKH-IPCSVCLSGLD

0.96091

1015 - 1586

571

TGNYQCGHYKH-HVVDGCNSSTC

0.99624

1015 - 1591

576

TGNYQCGHYKH-CNSSTCMMCYK

0.01037

1015 - 1594

579

TGNYQCGHYKH-STCMMCYKRNR

0.82162

1015 - 1605

590

TGNYQCGHYKH-ATRVECTTIVN

0.01042

1015 - 1627

612

TGNYQCGHYKH-GGKGFCKLHNW

0.41412

1015 - 1634

619

TGNYQCGHYKH-LHNWNCVNCDT

0.99581

1015 - 1637

622

TGNYQCGHYKH-WNCVNCDTFCA

0.99898

1015 - 1641

626

TGNYQCGHYKH-NCDTFCAGSTF

0.01125

1015 - 1731

716

TGNYQCGHYKH-DGKSKCEESSA

0.01037

1015 - 1748

733

TGNYQCGHYKH-YSQLMCQPILL

0.01062

1015 - 1836

821

TGNYQCGHYKH-KDVVECLKLSH

0.0106

1015 - 1852

837

TGNYQCGHYKH-VTGDSCNNYML

0.01125

1015 - 1873

858

TGNYQCGHYKH-RDLGACIDCSA

0.01093

1015 - 1876

861

TGNYQCGHYKH-GACIDCSARHI

0.99476

1015 - 1926

911

TGNYQCGHYKH-PFKLTCATTRQ

0.01053

1029 - 1071

42

KETLYCIDGAL-LDGVVCTEIDP

0.0118

1029 - 1114

85

KETLYCIDGAL-NFKFVCDNIKF

0.01383

1029 - 1191

162

KETLYCIDGAL-KPNTWCIRCLW

0.0104

1029 - 1194

165

KETLYCIDGAL-TWCIRCLWSTK

0.01047

1029 - 1223

194

KETLYCIDGAL-MDNLACEDLKP

0.01764

1029 - 1246

217

KETLYCIDGAL-KDVLECNVKTT

0.01047

1029 - 1342

313

KETLYCIDGAL-NIVTRCLNRVC

0.01038

1029 - 1347

318

KETLYCIDGAL-CLNRVCTNYMP

0.01314

1029 - 1362

333

KETLYCIDGAL-LLLQLCTFTRS

0.01278

1029 - 1392

363

KETLYCIDGAL-SVGKFCLEASF

0.01042

1029 - 1421

392

KETLYCIDGAL-LLLSVCLGSLI

0.01214

1029 - 1445

416

KETLYCIDGAL-GMPSYCTGYRE

0.01049

1029 - 1464

435

KETLYCIDGAL-TIATYCTGSIP

0.01113

1029 - 1470

441

KETLYCIDGAL-TGSIPCSVCLS

0.01279

1029 - 1473

444

KETLYCIDGAL-IPCSVCLSGLD

0.01079

1029 - 1586

557

KETLYCIDGAL-HVVDGCNSSTC

0.01038

1029 - 1591

562

KETLYCIDGAL-CNSSTCMMCYK

0.01038

1029 - 1594

565

KETLYCIDGAL-STCMMCYKRNR

0.01041

1029 - 1605

576

KETLYCIDGAL-ATRVECTTIVN

0.01677

1029 - 1627

598

KETLYCIDGAL-GGKGFCKLHNW

0.12146

1029 - 1634

605

KETLYCIDGAL-LHNWNCVNCDT

0.01044

1029 - 1637

608

KETLYCIDGAL-WNCVNCDTFCA

0.01052

1029 - 1641

612

KETLYCIDGAL-NCDTFCAGSTF

0.99904

1029 - 1731

702

KETLYCIDGAL-DGKSKCEESSA

0.01213

1029 - 1748

719

KETLYCIDGAL-YSQLMCQPILL

0.02934

1029 - 1836

807

KETLYCIDGAL-KDVVECLKLSH

0.0104

1029 - 1852

823

KETLYCIDGAL-VTGDSCNNYML

0.01231

1029 - 1873

844

KETLYCIDGAL-RDLGACIDCSA

0.01104

1029 - 1876

847

KETLYCIDGAL-GACIDCSARHI

0.0106

1029 - 1926

897

KETLYCIDGAL-PFKLTCATTRQ

0.01038

1071 - 1114

43

LDGVVCTEIDP-NFKFVCDNIKF

0.01042

1071 - 1191

120

LDGVVCTEIDP-KPNTWCIRCLW

0.01051

1071 - 1194

123

LDGVVCTEIDP-TWCIRCLWSTK

0.01039

1071 - 1223

152

LDGVVCTEIDP-MDNLACEDLKP

0.01059

1071 - 1246

175

LDGVVCTEIDP-KDVLECNVKTT

0.01055

1071 - 1342

271

LDGVVCTEIDP-NIVTRCLNRVC

0.01038

1071 - 1347

276

LDGVVCTEIDP-CLNRVCTNYMP

0.01037

1071 - 1362

291

LDGVVCTEIDP-LLLQLCTFTRS

0.01039

1071 - 1392

321

LDGVVCTEIDP-SVGKFCLEASF

0.01037

1071 - 1421

350

LDGVVCTEIDP-LLLSVCLGSLI

0.01037

1071 - 1445

374

LDGVVCTEIDP-GMPSYCTGYRE

0.01039

1071 - 1464

393

LDGVVCTEIDP-TIATYCTGSIP

0.0127

1071 - 1470

399

LDGVVCTEIDP-TGSIPCSVCLS

0.01038

1071 - 1473

402

LDGVVCTEIDP-IPCSVCLSGLD

0.01039

1071 - 1586

515

LDGVVCTEIDP-HVVDGCNSSTC

0.01045

1071 - 1591

520

LDGVVCTEIDP-CNSSTCMMCYK

0.01037

1071 - 1594

523

LDGVVCTEIDP-STCMMCYKRNR

0.01128

1071 - 1605

534

LDGVVCTEIDP-ATRVECTTIVN

0.01041

1071 - 1627

556

LDGVVCTEIDP-GGKGFCKLHNW

0.01536

1071 - 1634

563

LDGVVCTEIDP-LHNWNCVNCDT

0.01043

1071 - 1637

566

LDGVVCTEIDP-WNCVNCDTFCA

0.01104

1071 - 1641

570

LDGVVCTEIDP-NCDTFCAGSTF

0.01044

1071 - 1731

660

LDGVVCTEIDP-DGKSKCEESSA

0.01038

1071 - 1748

677

LDGVVCTEIDP-YSQLMCQPILL

0.01041

1071 - 1836

765

LDGVVCTEIDP-KDVVECLKLSH

0.01037

1071 - 1852

781

LDGVVCTEIDP-VTGDSCNNYML

0.01039

1071 - 1873

802

LDGVVCTEIDP-RDLGACIDCSA

0.01041

1071 - 1876

805

LDGVVCTEIDP-GACIDCSARHI

0.01092

1071 - 1926

855

LDGVVCTEIDP-PFKLTCATTRQ

0.01037

1114 - 1191

77

NFKFVCDNIKF-KPNTWCIRCLW

0.99729

1114 - 1194

80

NFKFVCDNIKF-TWCIRCLWSTK

0.95189

1114 - 1223

109

NFKFVCDNIKF-MDNLACEDLKP

0.07304

1114 - 1246

132

NFKFVCDNIKF-KDVLECNVKTT

0.99679

1114 - 1342

228

NFKFVCDNIKF-NIVTRCLNRVC

0.01336

1114 - 1347

233

NFKFVCDNIKF-CLNRVCTNYMP

0.02396

1114 - 1362

248

NFKFVCDNIKF-LLLQLCTFTRS

0.99958

1114 - 1392

278

NFKFVCDNIKF-SVGKFCLEASF

0.01533

1114 - 1421

307

NFKFVCDNIKF-LLLSVCLGSLI

0.99836

1114 - 1445

331

NFKFVCDNIKF-GMPSYCTGYRE

0.99832

1114 - 1464

350

NFKFVCDNIKF-TIATYCTGSIP

0.99695

1114 - 1470

356

NFKFVCDNIKF-TGSIPCSVCLS

0.99671

1114 - 1473

359

NFKFVCDNIKF-IPCSVCLSGLD

0.01039

1114 - 1586

472

NFKFVCDNIKF-HVVDGCNSSTC

0.05243

1114 - 1591

477

NFKFVCDNIKF-CNSSTCMMCYK

0.98088

1114 - 1594

480

NFKFVCDNIKF-STCMMCYKRNR

0.99729

1114 - 1605

491

NFKFVCDNIKF-ATRVECTTIVN

0.99695

1114 - 1627

513

NFKFVCDNIKF-GGKGFCKLHNW

0.99735

1114 - 1634

520

NFKFVCDNIKF-LHNWNCVNCDT

0.99707

1114 - 1637

523

NFKFVCDNIKF-WNCVNCDTFCA

0.99716

1114 - 1641

527

NFKFVCDNIKF-NCDTFCAGSTF

0.99867

1114 - 1731

617

NFKFVCDNIKF-DGKSKCEESSA

0.99738

1114 - 1748

634

NFKFVCDNIKF-YSQLMCQPILL

0.99836

1114 - 1836

722

NFKFVCDNIKF-KDVVECLKLSH

0.01385

1114 - 1852

738

NFKFVCDNIKF-VTGDSCNNYML

0.99731

1114 - 1873

759

NFKFVCDNIKF-RDLGACIDCSA

0.05932

1114 - 1876

762

NFKFVCDNIKF-GACIDCSARHI

0.99737

1114 - 1926

812

NFKFVCDNIKF-PFKLTCATTRQ

0.98052

1191 - 1194

3

KPNTWCIRCLW-TWCIRCLWSTK

0.01126

1191 - 1223

32

KPNTWCIRCLW-MDNLACEDLKP

0.01088

1191 - 1246

55

KPNTWCIRCLW-KDVLECNVKTT

0.01833

1191 - 1342

151

KPNTWCIRCLW-NIVTRCLNRVC

0.0104

1191 - 1347

156

KPNTWCIRCLW-CLNRVCTNYMP

0.01039

1191 - 1362

171

KPNTWCIRCLW-LLLQLCTFTRS

0.01038

1191 - 1392

201

KPNTWCIRCLW-SVGKFCLEASF

0.01038

1191 - 1421

230

KPNTWCIRCLW-LLLSVCLGSLI

0.01037

1191 - 1445

254

KPNTWCIRCLW-GMPSYCTGYRE

0.01057

1191 - 1464

273

KPNTWCIRCLW-TIATYCTGSIP

0.01123

1191 - 1470

279

KPNTWCIRCLW-TGSIPCSVCLS

0.78931

1191 - 1473

282

KPNTWCIRCLW-IPCSVCLSGLD

0.01361

1191 - 1586

395

KPNTWCIRCLW-HVVDGCNSSTC

0.04219

1191 - 1591

400

KPNTWCIRCLW-CNSSTCMMCYK

0.01132

1191 - 1594

403

KPNTWCIRCLW-STCMMCYKRNR

0.01068

1191 - 1605

414

KPNTWCIRCLW-ATRVECTTIVN

0.01059

1191 - 1627

436

KPNTWCIRCLW-GGKGFCKLHNW

0.01042

1191 - 1634

443

KPNTWCIRCLW-LHNWNCVNCDT

0.01812

1191 - 1637

446

KPNTWCIRCLW-WNCVNCDTFCA

0.14953

1191 - 1641

450

KPNTWCIRCLW-NCDTFCAGSTF

0.99048

1191 - 1731

540

KPNTWCIRCLW-DGKSKCEESSA

0.01183

1191 - 1748

557

KPNTWCIRCLW-YSQLMCQPILL

0.9729

1191 - 1836

645

KPNTWCIRCLW-KDVVECLKLSH

0.01189

1191 - 1852

661

KPNTWCIRCLW-VTGDSCNNYML

0.99719

1191 - 1873

682

KPNTWCIRCLW-RDLGACIDCSA

0.01038

1191 - 1876

685

KPNTWCIRCLW-GACIDCSARHI

0.01119

1191 - 1926

735

KPNTWCIRCLW-PFKLTCATTRQ

0.01128

1194 - 1223

29

TWCIRCLWSTK-MDNLACEDLKP

0.01038

1194 - 1246

52

TWCIRCLWSTK-KDVLECNVKTT

0.01038

1194 - 1342

148

TWCIRCLWSTK-NIVTRCLNRVC

0.01037

1194 - 1347

153

TWCIRCLWSTK-CLNRVCTNYMP

0.01037

1194 - 1362

168

TWCIRCLWSTK-LLLQLCTFTRS

0.0104

1194 - 1392

198

TWCIRCLWSTK-SVGKFCLEASF

0.01037

1194 - 1421

227

TWCIRCLWSTK-LLLSVCLGSLI

0.01037

1194 - 1445

251

TWCIRCLWSTK-GMPSYCTGYRE

0.01045

1194 - 1464

270

TWCIRCLWSTK-TIATYCTGSIP

0.01038

1194 - 1470

276

TWCIRCLWSTK-TGSIPCSVCLS

0.0135

1194 - 1473

279

TWCIRCLWSTK-IPCSVCLSGLD

0.01038

1194 - 1586

392

TWCIRCLWSTK-HVVDGCNSSTC

0.01038

1194 - 1591

397

TWCIRCLWSTK-CNSSTCMMCYK

0.01039

1194 - 1594

400

TWCIRCLWSTK-STCMMCYKRNR

0.01235

1194 - 1605

411

TWCIRCLWSTK-ATRVECTTIVN

0.01037

1194 - 1627

433

TWCIRCLWSTK-GGKGFCKLHNW

0.13936

1194 - 1634

440

TWCIRCLWSTK-LHNWNCVNCDT

0.01039

1194 - 1637

443

TWCIRCLWSTK-WNCVNCDTFCA

0.01041

1194 - 1641

447

TWCIRCLWSTK-NCDTFCAGSTF

0.91367

1194 - 1731

537

TWCIRCLWSTK-DGKSKCEESSA

0.01062

1194 - 1748

554

TWCIRCLWSTK-YSQLMCQPILL

0.15434

1194 - 1836

642

TWCIRCLWSTK-KDVVECLKLSH

0.01046

1194 - 1852

658

TWCIRCLWSTK-VTGDSCNNYML

0.01163

1194 - 1873

679

TWCIRCLWSTK-RDLGACIDCSA

0.01037

1194 - 1876

682

TWCIRCLWSTK-GACIDCSARHI

0.01044

1194 - 1926

732

TWCIRCLWSTK-PFKLTCATTRQ

0.01038

1223 - 1246

23

MDNLACEDLKP-KDVLECNVKTT

0.01062

1223 - 1342

119

MDNLACEDLKP-NIVTRCLNRVC

0.01037

1223 - 1347

124

MDNLACEDLKP-CLNRVCTNYMP

0.01038

1223 - 1362

139

MDNLACEDLKP-LLLQLCTFTRS

0.01037

1223 - 1392

169

MDNLACEDLKP-SVGKFCLEASF

0.01037

1223 - 1421

198

MDNLACEDLKP-LLLSVCLGSLI

0.01037

1223 - 1445

222

MDNLACEDLKP-GMPSYCTGYRE

0.86776

1223 - 1464

241

MDNLACEDLKP-TIATYCTGSIP

0.01074

1223 - 1470

247

MDNLACEDLKP-TGSIPCSVCLS

0.01123

1223 - 1473

250

MDNLACEDLKP-IPCSVCLSGLD

0.01038

1223 - 1586

363

MDNLACEDLKP-HVVDGCNSSTC

0.01038

1223 - 1591

368

MDNLACEDLKP-CNSSTCMMCYK

0.01148

1223 - 1594

371

MDNLACEDLKP-STCMMCYKRNR

0.99558

1223 - 1605

382

MDNLACEDLKP-ATRVECTTIVN

0.01111

1223 - 1627

404

MDNLACEDLKP-GGKGFCKLHNW

0.99721

1223 - 1634

411

MDNLACEDLKP-LHNWNCVNCDT

0.01045

1223 - 1637

414

MDNLACEDLKP-WNCVNCDTFCA

0.01078

1223 - 1641

418

MDNLACEDLKP-NCDTFCAGSTF

0.01057

1223 - 1731

508

MDNLACEDLKP-DGKSKCEESSA

0.28876

1223 - 1748

525

MDNLACEDLKP-YSQLMCQPILL

0.0105

1223 - 1836

613

MDNLACEDLKP-KDVVECLKLSH

0.01037

1223 - 1852

629

MDNLACEDLKP-VTGDSCNNYML

0.0171

1223 - 1873

650

MDNLACEDLKP-RDLGACIDCSA

0.01037

1223 - 1876

653

MDNLACEDLKP-GACIDCSARHI

0.01072

1223 - 1926

703

MDNLACEDLKP-PFKLTCATTRQ

0.01056

1246 - 1342

96

KDVLECNVKTT-NIVTRCLNRVC

0.01039

1246 - 1347

101

KDVLECNVKTT-CLNRVCTNYMP

0.0104

1246 - 1362

116

KDVLECNVKTT-LLLQLCTFTRS

0.01038

1246 - 1392

146

KDVLECNVKTT-SVGKFCLEASF

0.01037

1246 - 1421

175

KDVLECNVKTT-LLLSVCLGSLI

0.01037

1246 - 1445

199

KDVLECNVKTT-GMPSYCTGYRE

0.99572

1246 - 1464

218

KDVLECNVKTT-TIATYCTGSIP

0.05648

1246 - 1470

224

KDVLECNVKTT-TGSIPCSVCLS

0.52491

1246 - 1473

227

KDVLECNVKTT-IPCSVCLSGLD

0.01276

1246 - 1586

340

KDVLECNVKTT-HVVDGCNSSTC

0.01078

1246 - 1591

345

KDVLECNVKTT-CNSSTCMMCYK

0.01152

1246 - 1594

348

KDVLECNVKTT-STCMMCYKRNR

0.99721

1246 - 1605

359

KDVLECNVKTT-ATRVECTTIVN

0.01768

1246 - 1627

381

KDVLECNVKTT-GGKGFCKLHNW

0.99729

1246 - 1634

388

KDVLECNVKTT-LHNWNCVNCDT

0.02408

1246 - 1637

391

KDVLECNVKTT-WNCVNCDTFCA

0.41161

1246 - 1641

395

KDVLECNVKTT-NCDTFCAGSTF

0.04958

1246 - 1731

485

KDVLECNVKTT-DGKSKCEESSA

0.95465

1246 - 1748

502

KDVLECNVKTT-YSQLMCQPILL

0.65331

1246 - 1836

590

KDVLECNVKTT-KDVVECLKLSH

0.01118

1246 - 1852

606

KDVLECNVKTT-VTGDSCNNYML

0.9997

1246 - 1873

627

KDVLECNVKTT-RDLGACIDCSA

0.01037

1246 - 1876

630

KDVLECNVKTT-GACIDCSARHI

0.24485

1246 - 1926

680

KDVLECNVKTT-PFKLTCATTRQ

0.01184

1342 - 1347

5

NIVTRCLNRVC-CLNRVCTNYMP

0.28257

1342 - 1362

20

NIVTRCLNRVC-LLLQLCTFTRS

0.052

1342 - 1392

50

NIVTRCLNRVC-SVGKFCLEASF

0.01538

1342 - 1421

79

NIVTRCLNRVC-LLLSVCLGSLI

0.01149

1342 - 1445

103

NIVTRCLNRVC-GMPSYCTGYRE

0.01042

1342 - 1464

122

NIVTRCLNRVC-TIATYCTGSIP

0.01037

1342 - 1470

128

NIVTRCLNRVC-TGSIPCSVCLS

0.57621

1342 - 1473

131

NIVTRCLNRVC-IPCSVCLSGLD

0.2482

1342 - 1586

244

NIVTRCLNRVC-HVVDGCNSSTC

0.01042

1342 - 1591

249

NIVTRCLNRVC-CNSSTCMMCYK

0.0104

1342 - 1594

252

NIVTRCLNRVC-STCMMCYKRNR

0.01452

1342 - 1605

263

NIVTRCLNRVC-ATRVECTTIVN

0.07578

1342 - 1627

285

NIVTRCLNRVC-GGKGFCKLHNW

0.01293

1342 - 1634

292

NIVTRCLNRVC-LHNWNCVNCDT

0.01062

1342 - 1637

295

NIVTRCLNRVC-WNCVNCDTFCA

0.01091

1342 - 1641

299

NIVTRCLNRVC-NCDTFCAGSTF

0.96899

1342 - 1731

389

NIVTRCLNRVC-DGKSKCEESSA

0.01053

1342 - 1748

406

NIVTRCLNRVC-YSQLMCQPILL

0.12837

1342 - 1836

494

NIVTRCLNRVC-KDVVECLKLSH

0.01139

1342 - 1852

510

NIVTRCLNRVC-VTGDSCNNYML

0.29152

1342 - 1873

531

NIVTRCLNRVC-RDLGACIDCSA

0.01224

1342 - 1876

534

NIVTRCLNRVC-GACIDCSARHI

0.01039

1342 - 1926

584

NIVTRCLNRVC-PFKLTCATTRQ

0.0104

1347 - 1362

15

CLNRVCTNYMP-LLLQLCTFTRS

0.01042

1347 - 1392

45

CLNRVCTNYMP-SVGKFCLEASF

0.01038

1347 - 1421

74

CLNRVCTNYMP-LLLSVCLGSLI

0.01037

1347 - 1445

98

CLNRVCTNYMP-GMPSYCTGYRE

0.01048

1347 - 1464

117

CLNRVCTNYMP-TIATYCTGSIP

0.01039

1347 - 1470

123

CLNRVCTNYMP-TGSIPCSVCLS

0.04564

1347 - 1473

126

CLNRVCTNYMP-IPCSVCLSGLD

0.01111

1347 - 1586

239

CLNRVCTNYMP-HVVDGCNSSTC

0.01039

1347 - 1591

244

CLNRVCTNYMP-CNSSTCMMCYK

0.0104

1347 - 1594

247

CLNRVCTNYMP-STCMMCYKRNR

0.01037

1347 - 1605

258

CLNRVCTNYMP-ATRVECTTIVN

0.01096

1347 - 1627

280

CLNRVCTNYMP-GGKGFCKLHNW

0.0104

1347 - 1634

287

CLNRVCTNYMP-LHNWNCVNCDT

0.01041

1347 - 1637

290

CLNRVCTNYMP-WNCVNCDTFCA

0.01097

1347 - 1641

294

CLNRVCTNYMP-NCDTFCAGSTF

0.24593

1347 - 1731

384

CLNRVCTNYMP-DGKSKCEESSA

0.01046

1347 - 1748

401

CLNRVCTNYMP-YSQLMCQPILL

0.0134

1347 - 1836

489

CLNRVCTNYMP-KDVVECLKLSH

0.01046

1347 - 1852

505

CLNRVCTNYMP-VTGDSCNNYML

0.04128

1347 - 1873

526

CLNRVCTNYMP-RDLGACIDCSA

0.01038

1347 - 1876

529

CLNRVCTNYMP-GACIDCSARHI

0.01038

1347 - 1926

579

CLNRVCTNYMP-PFKLTCATTRQ

0.01037

1362 - 1392

30

LLLQLCTFTRS-SVGKFCLEASF

0.01072

1362 - 1421

59

LLLQLCTFTRS-LLLSVCLGSLI

0.01041

1362 - 1445

83

LLLQLCTFTRS-GMPSYCTGYRE

0.0104

1362 - 1464

102

LLLQLCTFTRS-TIATYCTGSIP

0.0106

1362 - 1470

108

LLLQLCTFTRS-TGSIPCSVCLS

0.04317

1362 - 1473

111

LLLQLCTFTRS-IPCSVCLSGLD

0.03466

1362 - 1586

224

LLLQLCTFTRS-HVVDGCNSSTC

0.01047

1362 - 1591

229

LLLQLCTFTRS-CNSSTCMMCYK

0.01045

1362 - 1594

232

LLLQLCTFTRS-STCMMCYKRNR

0.01043

1362 - 1605

243

LLLQLCTFTRS-ATRVECTTIVN

0.03247

1362 - 1627

265

LLLQLCTFTRS-GGKGFCKLHNW

0.01085

1362 - 1634

272

LLLQLCTFTRS-LHNWNCVNCDT

0.01045

1362 - 1637

275

LLLQLCTFTRS-WNCVNCDTFCA

0.01098

1362 - 1641

279

LLLQLCTFTRS-NCDTFCAGSTF

0.04387

1362 - 1731

369

LLLQLCTFTRS-DGKSKCEESSA

0.01058

1362 - 1748

386

LLLQLCTFTRS-YSQLMCQPILL

0.34243

1362 - 1836

474

LLLQLCTFTRS-KDVVECLKLSH

0.01063

1362 - 1852

490

LLLQLCTFTRS-VTGDSCNNYML

0.35499

1362 - 1873

511

LLLQLCTFTRS-RDLGACIDCSA

0.01098

1362 - 1876

514

LLLQLCTFTRS-GACIDCSARHI

0.01051

1362 - 1926

564

LLLQLCTFTRS-PFKLTCATTRQ

0.0104

1392 - 1421

29

SVGKFCLEASF-LLLSVCLGSLI

0.01037

1392 - 1445

53

SVGKFCLEASF-GMPSYCTGYRE

0.01093

1392 - 1464

72

SVGKFCLEASF-TIATYCTGSIP

0.01039

1392 - 1470

78

SVGKFCLEASF-TGSIPCSVCLS

0.90011

1392 - 1473

81

SVGKFCLEASF-IPCSVCLSGLD

0.01305

1392 - 1586

194

SVGKFCLEASF-HVVDGCNSSTC

0.01089

1392 - 1591

199

SVGKFCLEASF-CNSSTCMMCYK

0.01061

1392 - 1594

202

SVGKFCLEASF-STCMMCYKRNR

0.01041

1392 - 1605

213

SVGKFCLEASF-ATRVECTTIVN

0.01097

1392 - 1627

235

SVGKFCLEASF-GGKGFCKLHNW

0.01044

1392 - 1634

242

SVGKFCLEASF-LHNWNCVNCDT

0.01144

1392 - 1637

245

SVGKFCLEASF-WNCVNCDTFCA

0.01497

1392 - 1641

249

SVGKFCLEASF-NCDTFCAGSTF

0.99916

1392 - 1731

339

SVGKFCLEASF-DGKSKCEESSA

0.01219

1392 - 1748

356

SVGKFCLEASF-YSQLMCQPILL

0.94345

1392 - 1836

444

SVGKFCLEASF-KDVVECLKLSH

0.01117

1392 - 1852

460

SVGKFCLEASF-VTGDSCNNYML

0.99494

1392 - 1873

481

SVGKFCLEASF-RDLGACIDCSA

0.01044

1392 - 1876

484

SVGKFCLEASF-GACIDCSARHI

0.01061

1392 - 1926

534

SVGKFCLEASF-PFKLTCATTRQ

0.01045

1421 - 1445

24

LLLSVCLGSLI-GMPSYCTGYRE

0.01037

1421 - 1464

43

LLLSVCLGSLI-TIATYCTGSIP

0.01038

1421 - 1470

49

LLLSVCLGSLI-TGSIPCSVCLS

0.01275

1421 - 1473

52

LLLSVCLGSLI-IPCSVCLSGLD

0.98934

1421 - 1586

165

LLLSVCLGSLI-HVVDGCNSSTC

0.01038

1421 - 1591

170

LLLSVCLGSLI-CNSSTCMMCYK

0.01037

1421 - 1594

173

LLLSVCLGSLI-STCMMCYKRNR

0.01188

1421 - 1605

184

LLLSVCLGSLI-ATRVECTTIVN

0.98595

1421 - 1627

206

LLLSVCLGSLI-GGKGFCKLHNW

0.01038

1421 - 1634

213

LLLSVCLGSLI-LHNWNCVNCDT

0.01427

1421 - 1637

216

LLLSVCLGSLI-WNCVNCDTFCA

0.01042

1421 - 1641

220

LLLSVCLGSLI-NCDTFCAGSTF

0.03987

1421 - 1731

310

LLLSVCLGSLI-DGKSKCEESSA

0.01039

1421 - 1748

327

LLLSVCLGSLI-YSQLMCQPILL

0.07691

1421 - 1836

415

LLLSVCLGSLI-KDVVECLKLSH

0.04576

1421 - 1852

431

LLLSVCLGSLI-VTGDSCNNYML

0.01536

1421 - 1873

452

LLLSVCLGSLI-RDLGACIDCSA

0.23973

1421 - 1876

455

LLLSVCLGSLI-GACIDCSARHI

0.01037

1421 - 1926

505

LLLSVCLGSLI-PFKLTCATTRQ

0.01087

1445 - 1464

19

GMPSYCTGYRE-TIATYCTGSIP

0.84139

1445 - 1470

25

GMPSYCTGYRE-TGSIPCSVCLS

0.01111

1445 - 1473

28

GMPSYCTGYRE-IPCSVCLSGLD

0.03314

1445 - 1586

141

GMPSYCTGYRE-HVVDGCNSSTC

0.01171

1445 - 1591

146

GMPSYCTGYRE-CNSSTCMMCYK

0.01037

1445 - 1594

149

GMPSYCTGYRE-STCMMCYKRNR

0.01181

1445 - 1605

160

GMPSYCTGYRE-ATRVECTTIVN

0.01069

1445 - 1627

182

GMPSYCTGYRE-GGKGFCKLHNW

0.01042

1445 - 1634

189

GMPSYCTGYRE-LHNWNCVNCDT

0.01102

1445 - 1637

192

GMPSYCTGYRE-WNCVNCDTFCA

0.02755

1445 - 1641

196

GMPSYCTGYRE-NCDTFCAGSTF

0.01086

1445 - 1731

286

GMPSYCTGYRE-DGKSKCEESSA

0.01037

1445 - 1748

303

GMPSYCTGYRE-YSQLMCQPILL

0.01084

1445 - 1836

391

GMPSYCTGYRE-KDVVECLKLSH

0.01057

1445 - 1852

407

GMPSYCTGYRE-VTGDSCNNYML

0.01087

1445 - 1873

428

GMPSYCTGYRE-RDLGACIDCSA

0.03762

1445 - 1876

431

GMPSYCTGYRE-GACIDCSARHI

0.95164

1445 - 1926

481

GMPSYCTGYRE-PFKLTCATTRQ

0.01041

1464 - 1470

6

TIATYCTGSIP-TGSIPCSVCLS

0.01102

1464 - 1473

9

TIATYCTGSIP-IPCSVCLSGLD

0.01055

1464 - 1586

122

TIATYCTGSIP-HVVDGCNSSTC

0.01039

1464 - 1591

127

TIATYCTGSIP-CNSSTCMMCYK

0.01038

1464 - 1594

130

TIATYCTGSIP-STCMMCYKRNR

0.99437

1464 - 1605

141

TIATYCTGSIP-ATRVECTTIVN

0.01056

1464 - 1627

163

TIATYCTGSIP-GGKGFCKLHNW

0.99719

1464 - 1634

170

TIATYCTGSIP-LHNWNCVNCDT

0.01115

1464 - 1637

173

TIATYCTGSIP-WNCVNCDTFCA

0.01172

1464 - 1641

177

TIATYCTGSIP-NCDTFCAGSTF

0.01283

1464 - 1731

267

TIATYCTGSIP-DGKSKCEESSA

0.01083

1464 - 1748

284

TIATYCTGSIP-YSQLMCQPILL

0.01072

1464 - 1836

372

TIATYCTGSIP-KDVVECLKLSH

0.01039

1464 - 1852

388

TIATYCTGSIP-VTGDSCNNYML

0.27525

1464 - 1873

409

TIATYCTGSIP-RDLGACIDCSA

0.01056

1464 - 1876

412

TIATYCTGSIP-GACIDCSARHI

0.01155

1464 - 1926

462

TIATYCTGSIP-PFKLTCATTRQ

0.01044

1470 - 1473

3

TGSIPCSVCLS-IPCSVCLSGLD

0.01072

1470 - 1586

116

TGSIPCSVCLS-HVVDGCNSSTC

0.01038

1470 - 1591

121

TGSIPCSVCLS-CNSSTCMMCYK

0.01037

1470 - 1594

124

TGSIPCSVCLS-STCMMCYKRNR

0.01568

1470 - 1605

135

TGSIPCSVCLS-ATRVECTTIVN

0.01048

1470 - 1627

157

TGSIPCSVCLS-GGKGFCKLHNW

0.15447

1470 - 1634

164

TGSIPCSVCLS-LHNWNCVNCDT

0.01049

1470 - 1637

167

TGSIPCSVCLS-WNCVNCDTFCA

0.01042

1470 - 1641

171

TGSIPCSVCLS-NCDTFCAGSTF

0.01173

1470 - 1731

261

TGSIPCSVCLS-DGKSKCEESSA

0.0104

1470 - 1748

278

TGSIPCSVCLS-YSQLMCQPILL

0.01044

1470 - 1836

366

TGSIPCSVCLS-KDVVECLKLSH

0.01037

1470 - 1852

382

TGSIPCSVCLS-VTGDSCNNYML

0.01045

1470 - 1873

403

TGSIPCSVCLS-RDLGACIDCSA

0.0105

1470 - 1876

406

TGSIPCSVCLS-GACIDCSARHI

0.01164

1470 - 1926

456

TGSIPCSVCLS-PFKLTCATTRQ

0.01037

1473 - 1586

113

IPCSVCLSGLD-HVVDGCNSSTC

0.01038

1473 - 1591

118

IPCSVCLSGLD-CNSSTCMMCYK

0.01924

1473 - 1594

121

IPCSVCLSGLD-STCMMCYKRNR

0.99714

1473 - 1605

132

IPCSVCLSGLD-ATRVECTTIVN

0.03066

1473 - 1627

154

IPCSVCLSGLD-GGKGFCKLHNW

0.99726

1473 - 1634

161

IPCSVCLSGLD-LHNWNCVNCDT

0.01071

1473 - 1637

164

IPCSVCLSGLD-WNCVNCDTFCA

0.0178

1473 - 1641

168

IPCSVCLSGLD-NCDTFCAGSTF

0.01107

1473 - 1731

258

IPCSVCLSGLD-DGKSKCEESSA

0.23244

1473 - 1748

275

IPCSVCLSGLD-YSQLMCQPILL

0.01416

1473 - 1836

363

IPCSVCLSGLD-KDVVECLKLSH

0.0104

1473 - 1852

379

IPCSVCLSGLD-VTGDSCNNYML

0.88891

1473 - 1873

400

IPCSVCLSGLD-RDLGACIDCSA

0.01121

1473 - 1876

403

IPCSVCLSGLD-GACIDCSARHI

0.02966

1473 - 1926

453

IPCSVCLSGLD-PFKLTCATTRQ

0.01074

1586 - 1591

5

HVVDGCNSSTC-CNSSTCMMCYK

0.01039

1586 - 1594

8

HVVDGCNSSTC-STCMMCYKRNR

0.93587

1586 - 1605

19

HVVDGCNSSTC-ATRVECTTIVN

0.02313

1586 - 1627

41

HVVDGCNSSTC-GGKGFCKLHNW

0.9967

1586 - 1634

48

HVVDGCNSSTC-LHNWNCVNCDT

0.0117

1586 - 1637

51

HVVDGCNSSTC-WNCVNCDTFCA

0.01141

1586 - 1641

55

HVVDGCNSSTC-NCDTFCAGSTF

0.99908

1586 - 1731

145

HVVDGCNSSTC-DGKSKCEESSA

0.01084

1586 - 1748

162

HVVDGCNSSTC-YSQLMCQPILL

0.01058

1586 - 1836

250

HVVDGCNSSTC-KDVVECLKLSH

0.01039

1586 - 1852

266

HVVDGCNSSTC-VTGDSCNNYML

0.09478

1586 - 1873

287

HVVDGCNSSTC-RDLGACIDCSA

0.02677

1586 - 1876

290

HVVDGCNSSTC-GACIDCSARHI

0.01068

1586 - 1926

340

HVVDGCNSSTC-PFKLTCATTRQ

0.0104

1591 - 1594

3

CNSSTCMMCYK-STCMMCYKRNR

0.72096

1591 - 1605

14

CNSSTCMMCYK-ATRVECTTIVN

0.01078

1591 - 1627

36

CNSSTCMMCYK-GGKGFCKLHNW

0.99698

1591 - 1634

43

CNSSTCMMCYK-LHNWNCVNCDT

0.01103

1591 - 1637

46

CNSSTCMMCYK-WNCVNCDTFCA

0.01042

1591 - 1641

50

CNSSTCMMCYK-NCDTFCAGSTF

0.01062

1591 - 1731

140

CNSSTCMMCYK-DGKSKCEESSA

0.01384

1591 - 1748

157

CNSSTCMMCYK-YSQLMCQPILL

0.01041

1591 - 1836

245

CNSSTCMMCYK-KDVVECLKLSH

0.01037

1591 - 1852

261

CNSSTCMMCYK-VTGDSCNNYML

0.0179

1591 - 1873

282

CNSSTCMMCYK-RDLGACIDCSA

0.01037

1591 - 1876

285

CNSSTCMMCYK-GACIDCSARHI

0.76446

1591 - 1926

335

CNSSTCMMCYK-PFKLTCATTRQ

0.0104

1594 - 1605

11

STCMMCYKRNR-ATRVECTTIVN

0.0104

1594 - 1627

33

STCMMCYKRNR-GGKGFCKLHNW

0.01231

1594 - 1634

40

STCMMCYKRNR-LHNWNCVNCDT

0.01037

1594 - 1637

43

STCMMCYKRNR-WNCVNCDTFCA

0.01037

1594 - 1641

47

STCMMCYKRNR-NCDTFCAGSTF

0.01249

1594 - 1731

137

STCMMCYKRNR-DGKSKCEESSA

0.01037

1594 - 1748

154

STCMMCYKRNR-YSQLMCQPILL

0.01049

1594 - 1836

242

STCMMCYKRNR-KDVVECLKLSH

0.01037

1594 - 1852

258

STCMMCYKRNR-VTGDSCNNYML

0.01039

1594 - 1873

279

STCMMCYKRNR-RDLGACIDCSA

0.01038

1594 - 1876

282

STCMMCYKRNR-GACIDCSARHI

0.01037

1594 - 1926

332

STCMMCYKRNR-PFKLTCATTRQ

0.01037

1605 - 1627

22

ATRVECTTIVN-GGKGFCKLHNW

0.99728

1605 - 1634

29

ATRVECTTIVN-LHNWNCVNCDT

0.06908

1605 - 1637

32

ATRVECTTIVN-WNCVNCDTFCA

0.02753

1605 - 1641

36

ATRVECTTIVN-NCDTFCAGSTF

0.53652

1605 - 1731

126

ATRVECTTIVN-DGKSKCEESSA

0.35269

1605 - 1748

143

ATRVECTTIVN-YSQLMCQPILL

0.50279

1605 - 1836

231

ATRVECTTIVN-KDVVECLKLSH

0.01158

1605 - 1852

247

ATRVECTTIVN-VTGDSCNNYML

0.99573

1605 - 1873

268

ATRVECTTIVN-RDLGACIDCSA

0.01037

1605 - 1876

271

ATRVECTTIVN-GACIDCSARHI

0.66758

1605 - 1926

321

ATRVECTTIVN-PFKLTCATTRQ

0.0117

1627 - 1634

7

GGKGFCKLHNW-LHNWNCVNCDT

0.01045

1627 - 1637

10

GGKGFCKLHNW-WNCVNCDTFCA

0.01039

1627 - 1641

14

GGKGFCKLHNW-NCDTFCAGSTF

0.01188

1627 - 1731

104

GGKGFCKLHNW-DGKSKCEESSA

0.01037

1627 - 1748

121

GGKGFCKLHNW-YSQLMCQPILL

0.01038

1627 - 1836

209

GGKGFCKLHNW-KDVVECLKLSH

0.01037

1627 - 1852

225

GGKGFCKLHNW-VTGDSCNNYML

0.01043

1627 - 1873

246

GGKGFCKLHNW-RDLGACIDCSA

0.01056

1627 - 1876

249

GGKGFCKLHNW-GACIDCSARHI

0.0106

1627 - 1926

299

GGKGFCKLHNW-PFKLTCATTRQ

0.01037

1634 - 1637

3

LHNWNCVNCDT-WNCVNCDTFCA

0.01056

1634 - 1641

7

LHNWNCVNCDT-NCDTFCAGSTF

0.01129

1634 - 1731

97

LHNWNCVNCDT-DGKSKCEESSA

0.01037

1634 - 1748

114

LHNWNCVNCDT-YSQLMCQPILL

0.01384

1634 - 1836

202

LHNWNCVNCDT-KDVVECLKLSH

0.01038

1634 - 1852

218

LHNWNCVNCDT-VTGDSCNNYML

0.01064

1634 - 1873

239

LHNWNCVNCDT-RDLGACIDCSA

0.01159

1634 - 1876

242

LHNWNCVNCDT-GACIDCSARHI

0.01105

1634 - 1926

292

LHNWNCVNCDT-PFKLTCATTRQ

0.01038

1637 - 1641

4

WNCVNCDTFCA-NCDTFCAGSTF

0.01061

1637 - 1731

94

WNCVNCDTFCA-DGKSKCEESSA

0.01037

1637 - 1748

111

WNCVNCDTFCA-YSQLMCQPILL

0.01043

1637 - 1836

199

WNCVNCDTFCA-KDVVECLKLSH

0.01039

1637 - 1852

215

WNCVNCDTFCA-VTGDSCNNYML

0.01052

1637 - 1873

236

WNCVNCDTFCA-RDLGACIDCSA

0.01052

1637 - 1876

239

WNCVNCDTFCA-GACIDCSARHI

0.02117

1637 - 1926

289

WNCVNCDTFCA-PFKLTCATTRQ

0.01041

1641 - 1731

90

NCDTFCAGSTF-DGKSKCEESSA

0.01194

1641 - 1748

107

NCDTFCAGSTF-YSQLMCQPILL

0.0738

1641 - 1836

195

NCDTFCAGSTF-KDVVECLKLSH

0.01079

1641 - 1852

211

NCDTFCAGSTF-VTGDSCNNYML

0.01337

1641 - 1873

232

NCDTFCAGSTF-RDLGACIDCSA

0.46484

1641 - 1876

235

NCDTFCAGSTF-GACIDCSARHI

0.01046

1641 - 1926

285

NCDTFCAGSTF-PFKLTCATTRQ

0.01076

1731 - 1748

17

DGKSKCEESSA-YSQLMCQPILL

0.01242

1731 - 1836

105

DGKSKCEESSA-KDVVECLKLSH

0.01037

1731 - 1852

121

DGKSKCEESSA-VTGDSCNNYML

0.97574

1731 - 1873

142

DGKSKCEESSA-RDLGACIDCSA

0.01038

1731 - 1876

145

DGKSKCEESSA-GACIDCSARHI

0.02076

1731 - 1926

195

DGKSKCEESSA-PFKLTCATTRQ

0.01203

1748 - 1836

88

YSQLMCQPILL-KDVVECLKLSH

0.01048

1748 - 1852

104

YSQLMCQPILL-VTGDSCNNYML

0.01739

1748 - 1873

125

YSQLMCQPILL-RDLGACIDCSA

0.01038

1748 - 1876

128

YSQLMCQPILL-GACIDCSARHI

0.01037

1748 - 1926

178

YSQLMCQPILL-PFKLTCATTRQ

0.01039

1836 - 1852

16

KDVVECLKLSH-VTGDSCNNYML

0.97837

1836 - 1873

37

KDVVECLKLSH-RDLGACIDCSA

0.01039

1836 - 1876

40

KDVVECLKLSH-GACIDCSARHI

0.01045

1836 - 1926

90

KDVVECLKLSH-PFKLTCATTRQ

0.01041

1852 - 1873

21

VTGDSCNNYML-RDLGACIDCSA

0.01037

1852 - 1876

24

VTGDSCNNYML-GACIDCSARHI

0.01046

1852 - 1926

74

VTGDSCNNYML-PFKLTCATTRQ

0.01039

1873 - 1876

3

RDLGACIDCSA-GACIDCSARHI

0.01038

1873 - 1926

53

RDLGACIDCSA-PFKLTCATTRQ

0.01038

1876 - 1926

50

GACIDCSARHI-PFKLTCATTRQ

0.01037
  • 15
    Editorial Board
  • 183
    Citations
  • 81
    Total Articles
  • 3829
    Likes

Journals List

Anesthesia and Critical Care

Archives of Clinical and Biomedical Research

Archives of Clinical and Medical Case Reports

Archives of Internal Medicine Research

Archives of Microbiology & Immunology

Archives of Nephrology and Urology

Archives of Physiotherapy and Rehabilitation

Archives of Veterinary Science and Medicine

Cardiology and Cardiovascular Medicine

Dental Research and Oral Health

Fortune Journal of Health Sciences

Fortune Journal of Rheumatology

International Journal of Applied Biology and Pharmaceutical Technology

International Journal of Plant, Animal and Environmental Sciences

Journal of Analytical Techniques and Research

Journal of Biotechnology and Biomedicine

Journal of Cancer Science and Clinical Therapeutics

Journal of Environmental Science and Public Health

Journal of Food Science and Nutrition Research

Journal of Nanotechnology Research

Journal of Ophthalmology and Research

Journal of Orthopaedics and Sports Medicine

Journal of Pediatrics, Perinatology and Child Health

Journal of Pharmacy and Pharmacology Research

Journal of Psychiatry and Psychiatric Disorders

Journal of Radiology and Clinical Imaging

Journal of Spine Research and Surgery

Journal of Surgery and Research

Journal of Womens Health and Development

Obstetrics and Gynecology Research

Other Links

More Links

Contact Us

11355 Richmond Ave #507,

Houston, TX 77082, USA
Telephone : +1-(979)-320-6096
Email : contact[at]fortunejournals.com

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved